Method for producing differentiated cells
The method uses autofluorescence and antigen expression to isolate differentiated cells from stem cells, addressing the inefficiency and cost of existing technologies by providing a scalable and affordable solution for clinical use.
Patent Information
- Application Number
- JP2026077017
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-04-30
- Publication Date
- 2026-11-19
AI Technical Summary
Current methods for isolating and purifying differentiated cells from stem cells, particularly induced pluripotent stem cells, are costly and inefficient, relying on labeled antibodies that are expensive and difficult to standardize for clinical applications.
A method utilizing autofluorescence and antigen expression levels to isolate and enrich differentiated cells without antibody labeling, employing a cell processing apparatus with a closed system for centrifugation and magnetic separation, enabling efficient separation and purification of differentiated cells.
Enables the easy and cost-effective separation and purification of differentiated cells suitable for clinical applications, reducing reliance on expensive labeled antibodies and improving the scalability of cell therapy.
Smart Images

Figure 2026182800000009 
Figure 2026182800000010 
Figure 2026182800000011
Abstract
Description
[Technical Field]
[0001] The present invention relates to a method for producing differentiated cells derived from stem cells. More specifically, the production method of the present invention includes a step of isolating differentiated cells from a cell population including stem cells and differentiated cells derived from said stem cells, based on at least the difference in autofluorescence between the stem cells and the differentiated cells. The present invention also relates to a method for enriching differentiated cells. More specifically, the enrichment method of the present invention includes a step of removing undifferentiated cells from a cell population including stem cells and differentiated cells derived from said stem cells, based on at least the difference in autofluorescence between the stem cells and the differentiated cells. [Background technology]
[0002] In recent years, research into regenerative medicine using differentiated cells derived from induced pluripotent stem cells (iPS cells) has been actively conducted. In particular, treatment methods that involve establishing iPS cells from a patient's somatic cells (e.g., peripheral blood mononuclear cells) and then transplanting various differentiated cells and organoids induced from these iPS cells into the patient (autologous transplantation) are attracting attention as treatment methods that can reduce the risk of rejection (Non-patent documents 1 and 2).
[0003] From the perspective of transplantation of differentiated cells and organoids, it would be ideal to induce starting cells such as iPS cells into the desired differentiated cells or organoids with 100% or near-100% accuracy, but this is extremely difficult. Therefore, typically, after the differentiation induction described above, the desired differentiated cells or organoids are purified by sorting or other methods. When performing such sorting, labeled antibodies are used, but if the goal is clinical application, it is necessary to prepare labeled antibodies that comply with the standards for biologically derived raw materials. [Prior art documents] [Non-patent literature]
[0004] [Non-Patent Document 1] Shinsuke Yoshida., et al., CLINICAL AND TRANSLATIONAL RESOURCE AND TECHNOLOGY INSIGHTS VOLUME 4, ISSUE 1, P51-66.E10, JANUARY 13, 2023 [Non-Patent Document 2] Madrid, M., et al., Current Protocols,1, e88. doi: 10.1002 / cpzl.88 [Overview of the Initiative] [Problems that the invention aims to solve]
[0005] Because labeled antibodies and other materials that meet the aforementioned standards for biologically derived raw materials are currently very expensive, attempts are being made to isolate and purify target differentiated cells and organoids without relying on antibody labeling, in order to promote the affordable widespread adoption of cell therapy in society. However, it is still difficult to say that an effective method exists. Accordingly, the object of the present invention is to develop an effective method for separating and purifying differentiated cells. Specifically, the object is to provide a method for producing differentiated cells derived from stem cells, comprising the step of isolating differentiated cells from a cell population comprising stem cells and differentiated cells derived from said stem cells, based on at least the difference in autofluorescence between the stem cells and the differentiated cells. The object of the present invention is also to provide a method for enriching differentiated cells, comprising the step of removing undifferentiated cells from a cell population comprising stem cells and differentiated cells derived from said stem cells, based on at least the difference in autofluorescence between the stem cells and the differentiated cells. [Means for solving the problem]
[0006] In cell sorting, it is common knowledge among those skilled in the art to attach fluorescent labels such as antibodies to cells before performing fluorescence detection. However, the inventors initially intended to utilize the autofluorescence of cells without attaching fluorescent labels such as antibodies in order to isolate target differentiated cells. After careful consideration and diligent research, the inventors decided to use not only autofluorescence but also the expression level of antigens specific to differentiated cells. Surprisingly, they succeeded in efficiently isolating target differentiated cells based on autofluorescence and other factors.
[0007] Furthermore, the inventors have previously researched the possibility of producing induced pluripotent stem cells and differentiated cells derived from them using a cell processing device with a specific configuration. Therefore, they intended to apply the aforementioned separation methods, such as those utilizing autofluorescence, to the induced pluripotent stem cells and differentiated cells produced using this cell processing device. Based on these findings, the inventors conducted further research, ultimately completing the present invention.
[0008] In other words, the present invention is as follows: [1] A method for producing differentiated cells derived from stem cells, comprising the step of isolating the differentiated cells from a cell population including stem cells and differentiated cells derived from the stem cells, based on the difference in autofluorescence between at least the stem cells and the differentiated cells. [2] The method according to [1], wherein the difference is determined by comparing the autofluorescence intensity of the stem cells, the autofluorescence intensity of the differentiated cells, and the expression level of antigens specific to the differentiated cells. [3] The method according to [2], wherein the difference is obtained by plotting at least two fluorescence intensities of the autofluorescence of the stem cells, at least two fluorescence intensities of the autofluorescence of the differentiated cells, and the expression level of an antigen specific to the differentiated cells on the same plane. [4] The method according to [3], wherein the two types of fluorescence intensities are fluorescence intensities having wavelengths of 500 nm to 550 nm and 430 nm to 500 nm. [5] The method according to any one of [1] to [4], wherein the stem cells are embryonic stem cells, induced pluripotent stem cells, or mesenchymal stem cells. [6] The method according to any one of [1] to [5], wherein the differentiated cells are nerve cells, blood cells, or cardiomyocytes. [7] The method according to [6], wherein the differentiated cells are cardiomyocytes. [8] The method according to any one of [1] to [7], wherein the stem cells are induced pluripotent stem cells, and the stem cells are cells produced using a cell processing apparatus, wherein the cell processing apparatus has a closed system portion in which a sealed container for material supply and a rotatable sealed chamber configured to perform centrifugation are connected via a connection pipeline, while maintaining the sealability of the closed system portion, in the rotatable sealed chamber, the stem cells are produced by the method for producing induced pluripotent stem cells, which comprises performing step (s1) of centrifuging blood cells from whole blood, and step (s2) of bringing an initialization factor into contact with the blood cells, and step (s3) of establishing induced pluripotent stem cells from the blood cells in this order. [9] A method for enriching differentiated cells, comprising the step of removing undifferentiated cells from a cell population comprising stem cells and differentiated cells derived from the stem cells, based at least on the difference in autofluorescence between each of the stem cells and the differentiated cells.
[10] The method according to [9], wherein the difference is determined by comparing the autofluorescence intensity of the stem cells, the autofluorescence intensity of the differentiated cells, and the expression level of an antigen specific to the differentiated cells.
[11] The method according to
[10] , wherein the difference is determined by plotting at least two types of autofluorescence intensities of the stem cells, at least two types of autofluorescence intensities of the differentiated cells, and the expression level of an antigen specific to the differentiated cells on the same plane, respectively.
[12] The method according to
[11] , wherein the two types of fluorescence intensities are the intensities of fluorescence having wavelengths of 500 nm to 550 nm and 430 nm to 500 nm.
[13] The method according to any one of [9] to
[12] , wherein the differentiated cells are nerve cells, blood cells, or cardiomyocytes.
[14] The method according to
[13] , wherein the differentiated cells are cardiomyocytes.
[15] The stem cells are induced pluripotent stem cells, and the stem cells are cells produced using a cell processing apparatus, wherein the cell processing apparatus has a closed system portion in which a sealed container for material supply and a rotatable sealed chamber configured to perform centrifugation are connected via a connection pipeline, and the stem cells are produced in the rotatable sealed chamber while maintaining the hermeticity of the closed system portion, by sequentially performing the step (s1) of centrifuging blood cells from whole blood, the step (s2) of bringing a reprogramming factor into contact with the blood cells, and the step (s3) of establishing induced pluripotent stem cells from the blood cells, in this order. The method according to any one of [9] to
[14] .
[16] The sealed chamber includes an inlet port and an outlet port, and is configured to allow inflow and outflow of materials through the inlet port and the outlet port in a state of being rotated for centrifugation or in a state where the rotation is stopped, wherein in the step (s1), the fraction containing the centrifuged blood cells remains in the sealed chamber, and the other fraction is discharged out of the sealed chamber, the method according to [8] or
[15] .
[17] The cell processing apparatus further includes, as a part of the configuration of the closed system portion, a magnetic separation column connected to the sealed chamber via a connection pipeline, wherein in the step (s1), after the centrifugation, the fraction containing blood cells remains in the sealed chamber, among the blood cells, lymphoid cells are further labeled with magnetic beads, sent to the magnetic separation column, and magnetically separated from other blood cells, and the lymphoid cells labeled with the magnetic beads are returned to the sealed chamber, The method according to
[16] .
[18] The method according to any one of [8] and
[15] to
[17] , wherein step (s2) is performed with the sealed chamber in either a rotated state or a stationary state, or a combination thereof.
[19] The shape of the internal space of the sealed chamber, as determined by the side walls surrounding the internal space, is cylindrical, and the geometric rotational centerline of the cylindrical shape coincides with the central axis of the rotational motion of the sealed chamber in centrifugal separation, The base area of the cylindrical shape is 90-200 cm². 2 And, In centrifugal separation, the relative centrifugal force acting on the contents within the sealed chamber is 100 to 500 G. The method described in either [8] or
[15] -
[18] .
[20] The method according to any one of [8] and
[15] to
[19] , wherein the capacity of the sealed chamber is 300 to 700 ml.
[21] The method according to any one of [8] and
[15] to
[20] , wherein the centrifugal separation in step (s1) is performed by adding a centrifugal separation medium for density gradient into the sealed chamber and carrying out density gradient centrifugal separation.
[22] The method according to any one of [8] and
[15] to
[21] , wherein at least the inner wall surface of the sealed chamber has a polycarbonate resin portion.
[23] The method according to any one of [8] and
[15] to
[22] , wherein steps (s2) and (s3) are performed in the presence of scaffolding material.
[24] The method according to
[23] , wherein step (s1) is performed in the presence of scaffolding material.
[25] The method according to
[23] or
[24] , wherein scaffolding material is adhered to the inner wall surface of the sealed chamber.
[26] The method according to any one of
[23] to
[25] , wherein the scaffolding material comprises laminin fragments, cell-adherent peptides and polyvinyl acetal resin, or cell-adherent peptides and poly(meth)acrylate resin.
[27] The method according to
[26] , wherein the cell-adherent peptide comprises Arg-Gly-Asp.
[28] The method according to any one of [8] and
[15] to
[27] , further comprising the step (s4) of expanding culture the induced pluripotent stem cells in the sealed chamber while maintaining the closedness of the closed system portion after the step (s3).
[29] The differentiated cells are differentiated cells derived from induced pluripotent stem cells, and the differentiated cells are as follows: A method for producing induced pluripotent stem cells, comprising steps (s1) to (s3) described in any one of [8] and
[15] to
[27] , The process further includes a step (s5) in which, after the above step (s3), the induced pluripotent stem cells present in the sealed chamber are differentiated while maintaining the closed nature of the closed system portion. The method according to any one of [8] and
[15] to
[27] , wherein in step (s5), materials necessary for differentiation induction are supplied into the sealed chamber, and the method is manufactured by a manufacturing method in which step (s5) is carried out in the sealed chamber.
[30] The method according to
[29] , further comprising the step (s4) of expanding the culture of the induced pluripotent stem cells in the sealed chamber while maintaining the closedness of the closed system portion between steps (s3) and (s5). [Effects of the Invention]
[0009] According to the present invention, differentiated cells and organoids of interest can be easily separated and purified without relying on labeling with antibodies or the like. Furthermore, since the present invention allows for the separation and purification of differentiated cells without any processing of the cells intended for production, it is possible to produce differentiated cells suitable for clinical applications and the like. [Brief explanation of the drawing]
[0010] [Figure 1] Figure 1 shows the autofluorescence-extracted image of induced cardiomyocytes from Example 1. [Figure 2] Figure 2 shows the iPS cells from Example 1 unfolded using autofluorescence. [Figure 3]Figure 3 shows the identification of cardiomyocyte-specific expression regions in Example 1. Induced cardiomyocytes were stained with SIRPa (CD172a), CD31, CD49a, CD90b, and CD140b. Then, cardiomyocyte-specific expression regions for SIRPa(+) / CD31(-), CD49a(-), CD90b(-), and CD140b(-) were identified. [Figure 4] Figure 4 is a diagram in which Figures 1 to 3 are superimposed on the same plot. [Figure 5] Figure 5 shows the gate settings used in the cell sorter of Example 1, in relation to Figure 4. Among the induced cardiomyocyte plots (gray), combinations that seemed likely to separate the iPS cell plot (light gray) and the SIRPa plot (dark gray) with a high cardiomyocyte ratio were unfolded using Ex488 / Em530 and Ex405 / Em450. Based on these results, a sorting gate was set in the portion of the SIRPa plot (dark gray) that did not include the iPS cell plot (light gray) but had a high cardiomyocyte ratio. [Figure 6] Figure 6 shows the results of staining the samples from Example 1 before sorting (left), after sorting by Gate-Others (center), and after sorting by Gate-CM (right) with troponin T, a myocardial-specific marker, to confirm the myocardial content. The results confirmed that the myocardial content was higher in the samples sorted by Gate-CM compared to the samples before sorting. [Figure 7]The upper left panel of Figure 7 shows the induced cardiomyocytes of Example 2 developed using autofluorescence. The upper center panel of Figure 7 shows the iPS cells of Example 2 developed using autofluorescence. The upper right panel of Figure 7 shows the identification of cardiomyocyte-specific expression regions in Example 2. Induced cardiomyocytes were stained with SIRPa (CD172a), CD31, CD49a, CD90b, and CD140b. Cardiomyocyte-specific expression regions of SIRPa(+) / CD31(-), CD49a(-), CD90b(-), and CD140b(-) were then identified. Regarding Figure 7, it shows the gate settings used in the cell sorter for Example 2. These were developed using Ex488 / Em525 and Ex405 / Em450. Among the induced cardiomyocyte plots (gray), it appeared possible to separate the iPS cell plot (light gray) and the SIRPa plot (dark gray), which had a higher proportion of cardiomyocytes (Figure 7, lower left). Based on these results, a sorting gate was set in the SIRPa plot (dark gray), which does not contain iPS cell plots (light gray) but has a high proportion of cardiomyocytes (Figure 7, lower right). [Figure 8] Figure 8 shows the expression rates of the undifferentiated markers TRA-1-60, OCT-4, and SSEA-4 in the sample before sorting (left) and after sorting with Gate-CM (right) in Example 2. The results showed that the expression rates of the undifferentiated markers TRA-1-60 and OCT-4 were lower in the sample sorted with Gate-CM compared to the sample before sorting, confirming that sorting reduced the proportion of undifferentiated cells. [Figure 9] Figure 9 is a block diagram showing an example of the configuration of the closed system portion of a cell processing apparatus used in the manufacturing method of the present invention. Each thick black line indicated by the symbol A10 represents a connecting conduit such as a flexible tube (the same applies to Figure 13). In addition, to clearly show the movement and stopping of material within the closed system portion, a pinch valve that opens and closes the connecting conduit and a peristaltic pump that delivers material are drawn on the connecting conduit. These pinch valve and peristaltic pump are located outside the connecting conduit and do not belong to the closed system portion, but belong to the mechanical part of the cell processing apparatus (the same applies to Figure 13). [Figure 10]Figure 10 is a schematic diagram showing the centrifugation process in a sealed chamber of a cell processing apparatus used in the manufacturing method of the present invention, and shows the inside of the sealed chamber. [Figure 11] Figure 11 is a photograph illustrating the mechanism of a cell processing apparatus used in the manufacturing method of the present invention. [Figure 12] Figure 12 is a photograph illustrating the state in which a closed system is attached to the mechanism of a cell processing apparatus in the present invention. [Figure 13] Figure 13 is a block diagram showing another example of the configuration of the closed system portion of the cell processing apparatus used in the manufacturing method of the present invention. [Figure 14] Figure 14 shows microscopic images of iPS cells in Example 9A at 24 and 28 days after establishment, and the results of confirming the expression of GFP, SSEA4, and TRA-1-60 loaded into the vector one week after each passage in passages 1 and 3. [Figure 15] Figure 15 shows microscopic images of iPS cells in Example 13A at 21 and 28 days after establishment, and the results of confirming the expression of GFP, SSEA4, and TRA-1-60 loaded into the vector one week after each passage in passages 1 and 3. [Figure 16] Figure 16 is a photographic diagram showing an example of a conventional cell processing apparatus. [Figure 17] Figure 17 shows the results of the investigation into the coating method for scaffolding materials in Examples 23A and 24A. [Figure 18] Figure 18 shows the results of the investigation into the monocyte differentiation process in Example 29A. [Figure 19] Figure 19 shows the results of the investigation into the monocyte differentiation process in Example 30A. [Figure 20] Figure 20 shows the induced cardiomyocytes from Example 3, unfolded using autofluorescence. [Figure 21] Figure 21 shows the iPS cells from Example 3 unfolded using autofluorescence. [Figure 22]Figure 22 shows the identification of cardiomyocyte-specific expression regions in Example 3. Induced cardiomyocytes were stained with SIRPa (CD172a), CD31, CD49a, CD90b, and CD140b. Then, cardiomyocyte-specific expression regions for SIRPa(+) / CD31(-), CD49a(-), CD90b(-), and CD140b(-) were identified. [Figure 23] Figure 23 is a diagram showing Figures 20 to 22 superimposed on the same plot. [Figure 24] Figure 24 is a diagram relating to Figure 23, showing the gate settings used in the cell sorter of Example 3. Among the induced cardiomyocyte plots (gray), combinations that seemed likely to separate the iPS cell plot (light gray) and the SIRPa plot (dark gray) with a high cardiomyocyte ratio were unfolded using Ex375 / Em450 and Ex488 / Em530 (left). Based on these results, a sorting gate was set for the portion of the SIRPa plot (dark gray) with a high cardiomyocyte ratio that did not include the iPS cell plot (light gray) (left). Furthermore, actual sorting was performed using the gate settings as shown in Figure 24 (left) (right). [Figure 25] Figure 25 shows the results of staining the samples from Example 3 before sorting (left), after sorting by Gate-Others (center), and after sorting by Gate-CM (right) with troponin T, a myocardial-specific marker, to confirm the myocardial percentage. The results confirmed that the myocardial percentage was higher in the samples sorted by Gate-CM compared to the samples sorted before sorting. [Modes for carrying out the invention]
[0011] 1. Manufacturing method of the present invention The present invention provides a method for producing differentiated cells derived from stem cells (hereinafter sometimes referred to as "the production method of the present invention"), which includes a step of isolating the differentiated cells from a cell population comprising stem cells and differentiated cells derived from the stem cells, based on at least the difference in autofluorescence between the stem cells and the differentiated cells.
[0012] In this specification, "autofluorescence" refers to fluorescence emitted by substances inherent in cells and tissues upon irradiation with an excitation wavelength. Examples of endogenous components that emit autofluorescence include coenzymes, proteins, amino acids, and pigments. More specifically, examples include NADH, NADPH, flavins (FAD, etc.), cholecalciferol, pyridoxine, collagen, elastin, lipofuscin, tryptophan, tyrosine, fibronectin, folic acid, and melanin.
[0013] In the present invention, it is not necessary to identify the endogenous component that emits autofluorescence, and the autofluorescence may include fluorescence emitted by endogenous components other than the endogenous component that emits autofluorescence as described above.
[0014] In the present invention, the difference in autofluorescence can be determined by comparing the autofluorescence intensity of stem cells, the autofluorescence intensity of differentiated cells, and the expression level of antigens specific to differentiated cells. The autofluorescence intensity is obtained by irradiating with excitation light of a specific wavelength and detecting the emitted fluorescence. The instrument for detecting fluorescence is not particularly limited as long as it can isolate the desired differentiated cells, but a known fluorescence detector may be used. Alternatively, a fluorescence detector such as one provided in a flow cytometer or cell sorter may be used. The autofluorescence intensity may consist of at least two types of fluorescence intensities (e.g., 2, 3, 4, 5 types, etc.). The expression level of the specific antigen may be one type or at least two types of antigens (e.g., 2, 3, 4, 5 types, etc.). Preferably, the expression level of the specific antigen is at least two types of antigens.
[0015] In the present invention, the autofluorescence intensity is not particularly limited as long as the desired differentiated cells can be isolated, but examples include fluorescence intensities with wavelengths of 250 nm to 850 nm (e.g., 431 nm, 450 nm, 510 nm, 525 nm, 530 nm, 610 nm, 710 nm, etc.), preferably 350 nm to 670 nm (maximum fluorescence wavelength). A more preferred fluorescence intensity is a combination of 500 nm to 550 nm and 430 nm to 500 nm. In one embodiment, the fluorescence intensity includes fluorescence intensities with wavelengths of 450 nm to 530 nm (maximum fluorescence wavelength). In another embodiment, the fluorescence intensity includes fluorescence intensities with wavelengths of 450 nm, 510 nm, and 530 nm (maximum fluorescence wavelength), with at least two wavelengths. In yet another embodiment, the fluorescence intensity includes fluorescence intensities with wavelengths of 450 nm and 530 nm (maximum fluorescence wavelength). In another embodiment, the fluorescence intensity includes the fluorescence intensity having wavelengths of 430 nm to 530 nm (maximum fluorescence wavelength). In one embodiment, the fluorescence intensity includes fluorescence intensities having at least two wavelengths among those having wavelengths of 431 nm, 510 nm, 525 nm, and 530 nm (maximum fluorescence wavelength).
[0016] The wavelength of the excitation light for emitting autofluorescence (hereinafter also referred to as the "excitation wavelength") may be one wavelength or at least two wavelengths. The excitation wavelength is not particularly limited as long as the desired differentiated cells can be isolated, but examples include wavelengths of 300 nm to 800 nm. In one embodiment, the excitation wavelength includes wavelengths of 375 nm to 488 nm. In another embodiment, the excitation wavelength includes at least two of the wavelengths of 375 nm, 405 nm, and 488 nm. In a further embodiment, the excitation wavelength includes wavelengths of 405 nm and 488 nm. In yet another further embodiment, the excitation wavelength includes wavelengths of 375 nm and 488 nm. Irradiation with excitation light having the wavelengths described above may be carried out using a known light source, such as a laser light source. Alternatively, the irradiation with excitation light may be carried out using a light source provided in a known instrument such as a cell sorter or a flow cytometer.
[0017] Depending on the specifications of the equipment such as cell sorters and flow cytometers, for the isolation of differentiated cells (e.g., cardiomyocytes), combinations of excitation wavelength 375 nm / maximum fluorescence wavelength 450 nm and excitation wavelength 488 nm / maximum fluorescence wavelength 530 nm, excitation wavelength 405 nm / maximum fluorescence wavelength 450 nm and excitation wavelength 488 nm / maximum fluorescence wavelength 530 nm, or excitation wavelength 488 nm / maximum fluorescence wavelength 525 nm and excitation wavelength 405 nm / maximum fluorescence wavelength 450 nm are more preferred. Of the above combinations, combinations of excitation wavelength 405 nm / maximum fluorescence wavelength 450 nm and excitation wavelength 488 nm / maximum fluorescence wavelength 530 nm, or excitation wavelength 488 nm / maximum fluorescence wavelength 525 nm and excitation wavelength 405 nm / maximum fluorescence wavelength 450 nm are even more preferred. Furthermore, combinations of excitation wavelength 375 nm / maximum fluorescence wavelength 450 nm and excitation wavelength 405 nm / maximum fluorescence wavelength 431 nm, excitation wavelength 375 nm / maximum fluorescence wavelength 450 nm and excitation wavelength 405 nm / maximum fluorescence wavelength 525 nm, excitation wavelength 405 nm / maximum fluorescence wavelength 431 nm and excitation wavelength 488 nm / maximum fluorescence wavelength 530 nm, excitation wavelength 405 nm / maximum fluorescence wavelength 431 nm and excitation wavelength 405 nm / maximum fluorescence wavelength 510 nm, or excitation wavelength 405 nm / maximum fluorescence wavelength 525 nm and excitation wavelength 488 nm / maximum fluorescence wavelength 530 nm are also preferred. Among the above combinations, the combination of excitation wavelength 375 nm / maximum fluorescence wavelength 450 nm and excitation wavelength 488 nm / maximum fluorescence wavelength 530 nm is even more preferred.
[0018] In the present invention, the expression level of a differentiated cell-specific antigen may be the expression level of the cell's surface antigen or the expression level of an internal antigen, but typically it is the expression level of the surface antigen. In the present invention, fluorescence intensity may be used as an indicator of the expression level of a differentiated cell-specific antigen, and this fluorescence intensity may be detected by known methods, for example, by using primary or secondary antibodies labeled with various fluorescent dyes that specifically bind to a desired antigen. Alternatively, the fluorescence intensity may be measured using known instruments, for example, a flow cytometer or a cell sorter, and measured by known methods. As an example of an internal antigen, in the case of sorting cardiomyocytes, the expression level of troponin T can be used as an indicator.
[0019] Antigens specific to differentiated cells may be appropriately selected using known techniques, etc., taking into consideration the differentiated cells to be isolated. For example, if the differentiated cells are cardiomyocytes, typically specific antigens such as SIRPa (CD172a), CD31, CD49a, CD90b, and CD140b may be used. If the differentiated cells are hematopoietic cells, typically, for example, CD34, CD43, and CD235ab may be used. If the differentiated cells are neural progenitor cells, typically, for example, ATRNL1, CD200, CELSR3, CHRM4, CNTNAP4, CXCR4, CXCR7, DSCAML1, EPHA5, ERBB4, FAM5B, FAM65B, FNDC5, GRIA1, GRIA4, L1CAM, NCAM1, NRCAM, NRXN3, NXPH1, PLXNA4, ROBO1, ROBO2, and TMEM2 may be used.
[0020] In the present invention, the comparison of the autofluorescence intensity of stem cells, the autofluorescence intensity of differentiated cells, and the expression level of antigens specific to differentiated cells may be performed by plotting at least two types of fluorescence intensities of stem cell autofluorescence, at least two types of fluorescence intensities of differentiated cells autofluorescence, and the expression level of at least one antigen specific to differentiated cells on the same plane, thereby determining the differences used in the separation step of the present invention. Specifically, for example, one of the two types of fluorescence intensities may be plotted on the vertical axis and the other on the horizontal axis, and the autofluorescence of stem cells, the autofluorescence of differentiated cells, and the expression level of antigens specific to differentiated cells (expression level is shown as fluorescence intensity) may be plotted on the same plane. Alternatively, one of the two types of fluorescence intensities may be plotted on the vertical axis and the other on the horizontal axis, and dot plots of the autofluorescence of stem cells, the autofluorescence of differentiated cells, and the expression level of antigens specific to differentiated cells (expression level is shown as fluorescence intensity) may be created, and then these plots may be superimposed to create a plot on the same plane. For example, when using commercially available instruments such as cell sorters or flow cytometers to observe the expression level of a specific antigen, a histogram will be produced with the horizontal axis representing antigen expression level and the vertical axis representing cell number. The distribution within this histogram where the antigen specific to the target differentiated cells is expressed can be identified within the original plot (a mixed group of differentiated and undifferentiated cells) by checking the software stored in the commercially available instrument.
[0021] The setting of differences used in the separation process of the present invention, including plotting on the same plane as described above, may be performed, for example, by applications provided in known flow cytometry or cell sorters, and this setting typically corresponds to gate setting (hierarchical gate setting). In the case of known cell sorters, etc., desired differentiated cells can be isolated using the gate set as described above.
[0022] When setting the gate as described above, the expression level of at least one antigen specific to differentiated cells (expression level is indicated by fluorescence intensity) may typically be set to the expression region of SIRPa(+) / CD31(-), CD49a(-), CD90b(-), and CD140b(-) if the differentiated cells are cardiomyocytes. Alternatively, if the differentiated cells are hematopoietic cells, it may typically be set to the expression region of CD34(+), CD43(+), and CD235ab(-).
[0023] In the separation process of the present invention as described above, the difference to be used in the separation process of the present invention may be set in advance with a small number of cells (e.g., 100,000 cells, etc.) (setting the gate), and then the actual separation process may be carried out. Specifically, for example, in the case of cardiomyocytes, combinations of excitation wavelength 375 nm / maximum fluorescence wavelength 450 nm and excitation wavelength 488 nm / maximum fluorescence wavelength 530 nm, or excitation wavelength 405 nm / maximum fluorescence wavelength 450 nm and excitation wavelength 488 nm / maximum fluorescence wavelength 530 nm are more preferred. In addition, a small number of cells (e.g., 100,000 cells, etc.) can be passed through an instrument such as a cell sorter or flow cytometer in advance and plotted to set the difference to be used in the separation process of the present invention (determining which two sets of excitation wavelength / maximum fluorescence wavelength combinations will be used as gates), and then the actual separation process may be carried out. This is because the target of separation in the present invention is living cells that are not fluorescently labeled, and therefore the conditions under which they can be separated most efficiently may differ depending on physiological conditions and the state of the cells.
[0024] The differentiation cell separation step of the present invention, including the setting of differences used in the separation step of the present invention, can be carried out using known cell sorters, etc. Commercial cell sorters include cell sorters manufactured by Becton Dickinson (BD) (for example, BD FACSAria). TM II, BD FACSAria TM III, BD FACSSymphony TM (etc.) and analysis software (e.g., FlowJo TM Analysis software, BD FACS Diva TMThis can be done using software installed on the device, or by using Sony's Cell Isolation System CGX10, Spectral Cell Analyzer SA3800, Cell Sorter MA900, etc.
[0025] (stem cells) In this specification, "stem cells" refers to cells that have the ability to self-replicate (self-renew) and differentiate. Examples of stem cells include pluripotent stem cells. The stem cells used in the manufacturing method of the present invention only need to be cells that have the ability to self-replicate (self-renew) and differentiate; therefore, cells such as those included in the "differentiated cells" described later may be used as stem cells in the manufacturing method of the present invention.
[0026] A "pluripotent stem cell" refers to a stem cell that can differentiate into various tissues and cells with different forms and functions in the living body, and has the ability to differentiate into any of the three germ layers (endoderm, mesoderm, and ectoderm). Examples of pluripotent stem cells used in this invention include induced pluripotent stem cells (iPS cells), embryonic stem cells (ES cells), nuclear transfer embryonic stem cells (ntES cells) derived from cloned embryos obtained by nuclear transfer, multipotent germline stem cells ("mGS cells"), and embryonic germline stem cells (EG cells), but iPS cells are preferred (more preferably human iPS cells). When the above-mentioned pluripotent stem cells are ES cells or any cells derived from a human embryo, the cells may be cells produced by destroying the embryo or cells produced without destroying the embryo, but from an ethical standpoint, cells produced without destroying the embryo are preferred.
[0027] As for the ES cell lines used in this invention, for example, if they are human ES cell lines, various human ES cell lines established by the University of Wisconsin, NIH, RIKEN, Kyoto University, National Center for Child Health and Development, and Cellartis, etc., can be used. Specifically, examples of human ES cell lines include CHB-1 to CHB-12, RUES1, RUES2, HUES1 to HUES28, etc. distributed by ESI Bio, H1, H9, etc. distributed by WiCell Research, and KhES-1, KhES-2, KhES-3, KhES-4, KhES-5, SSES1, SSES2, SSES3, etc. distributed by RIKEN.
[0028] iPS cells are cells obtained by reprogramming mammalian somatic cells or undifferentiated stem cells by introducing specific factors (nuclear reprogramming factors). Currently, there are various types of iPS cells. These include iPSCs established by Yamanaka et al. by introducing four factors—Oct3 / 4, Sox2, Klf4, and c-Myc—into mouse fibroblasts (Takahashi K, Yamanaka S., Cell, (2006) 126: 663-676), human cell-derived iPSCs established by introducing the same four factors into human fibroblasts (Takahashi K, Yamanaka S., et al. Cell, (2007) 131: 861-872), Nanog-iPSCs established by selecting cells based on Nanog expression after introducing the above four factors (Okita, K., Ichisaka, T., and Yamanaka, S. (2007). Nature 448, 313-317), and iPSCs produced using a method that does not include c-Myc (Nakagawa M, Yamanaka S., et al. Nature). Biotechnology, (2008) 26, 101-106), and iPSCs established by introducing six factors using a virus-free method (Okita K et al. Nat. Methods 2011 May;8(5):409-12, Okita K et al. Stem Cells. 31(3):458-66.) can also be used. In addition, induced pluripotent stem cells established by introducing the four factors OCT3 / 4, SOX2, NANOG, and LIN28, as created by Thomson et al. (Yu J., Thomson JA. et al., Science (2007) 318: 1917-1920), induced pluripotent stem cells created by Daley et al. (Park IH, Daley GQ. et al., Nature (2007) 451: 141-146), and induced pluripotent stem cells created by Sakurada et al. (Japanese Patent Publication No. 2008-307007) can also be used. In addition, all published papers (for example, Shi Y., Ding S., et al., Cell Stem Cell, (2008) Vol3, Issue 5, 568-574; Kim JB., Scholer HR., et al., Nature, (2008) 454, 646-650; Huangfu D., Melton, DA., et al., Nature Biotechnology, (2008) 26, No 7, Any induced pluripotent stem cells known in the art as described in patent publications 795-797) or (e.g., JP 2008-307007, JP 2008-283972, US2008-2336610, US2009-047263, WO2007-069666, WO2008-118220, WO2008-124133, WO2008-151058, WO2009-006930, WO2009-006997, WO2009-007852) can be used.
[0029] Various iPSC lines established by institutions such as the NIH, RIKEN, and Kyoto University are available as induced pluripotent stem cell lines. For example, human iPSC lines include RIKEN's HiPS-RIKEN-1A, HiPS-RIKEN-2A, HiPS-RIKEN-12A, and Nips-B2, and Kyoto University's 253G1, 253G4, 1201C1, 1205D1, 1210B2, 1383D2, 1383D6, 201B7, 409B2, 454E2, 606A1, 610B1, 648A1, 1231A3, Ff-I01s04, HHC0047E, and HHC0031A.
[0030] The origin of the pluripotent stem cells is not particularly limited and may include cells from rodents such as rats, mice, hamsters, and guinea pigs; lagomorphs such as rabbits; ungulates such as pigs, cattle, goats, and sheep; carnivores such as dogs and cats; and primates such as humans, monkeys, rhesus macaques, marmosets, orangutans, and chimpanzees. The preferred origin is human.
[0031] (differentiated cells) In this specification, "differentiated cells" refers to cells or organoids obtained by inducing differentiation of stem cells (e.g., pluripotent stem cells). The resulting cells may be undifferentiated cells such as stem cells or progenitor cells, or they may be terminally differentiated cells. In this specification, the term "differentiated cells" may be used to encompass both undifferentiated cells and terminally differentiated cells obtained by inducing differentiation of pluripotent stem cells. In this specification, "undifferentiated cells" means cells that have not reached terminal differentiation in the cell lineage, and examples of undifferentiated cells include stem cells, including pluripotent stem cells, and progenitor cells. Examples of stem cells or progenitor cells include ectodermal cells such as neural crest cells, neural stem cells, neural progenitor cells, glial progenitor cells, retinal stem cells, corneal stem cells, keratinocyte epidermal stem cells, melanocyte stem cells, and mammary gland stem cells; mesodermal cells such as hematopoietic progenitor cells, myeloid stem cells, lymphoid stem cells, B progenitor cells, T progenitor cells, mesenchymal stem cells, cardiac stem cells, cardiac progenitor cells, vascular endothelial progenitor cells, vascular pericytes, platelet progenitor cells, skeletal muscle stem cells, adipose stem cells, renal progenitor cells; and endodermal cells such as hepatic stem cells, hepatic progenitor cells, intestinal stem cells, and airway stem cells.
[0032] In this specification, "terminally differentiated cells" means cells that have reached terminal differentiation in a cell lineage. Terminally differentiated cells are not particularly limited, but include, for example, osteoblasts, chondrocytes, adipocytes, hepatocytes, hepatic mesothelial cells, cholangiocarpal epithelial cells, hepatic stellate cells, hepatic sinusoidal endothelial cells, Kupffer cells, pit cells, vascular endothelial cells, blood cells (e.g., leukocytes, erythrocytes, platelets), pancreatic ductal epithelial cells, pancreatic ductal cells, acinar central cells, acinar cells, islets of Langerhans, cardiomyocytes, fibroblasts, smooth muscle cells, type I alveolar epithelial cells, type II alveolar epithelial cells, Clara cells, ciliated epithelial cells, basal cells, goblet cells, neuroendocrine cells, Krutschki cells, tubular epithelial cells, urothelial cells, columnar epithelial cells, glomerular epithelial cells, glomerular endothelial cells, podocytes, mesangial cells, nerve cells, glial cells, etc. Examples of leukocytes include lymphocytes, granulocytes, and monocytes. The stem cells and differentiated cells described above can be produced using known methods such as those described in the "Differentiation Induction Methods" section below.
[0033] In the manufacturing method of the present invention, undifferentiated cells may be removed as appropriate. The method for removing undifferentiated cells is not particularly limited as long as cells other than those produced by the manufacturing method of the present invention (differentiated cells) can be removed, and can be carried out by adding a known undifferentiated cell removal agent to the culture medium (for example, Di Mao., et al. Angewandte Chemie International Edition; 9 January 2017, Ben-David, U., et al. Cell Stem Cell, 12, 167 (2013), WO2019 / 187918, JP 2016-93178, Yoshiki Nakashima, et. al., Molecular Therapy Vol. 26 No 7 July 2018, etc.).
[0034] Quality inspections may be performed as appropriate to determine whether the cells, organoids, etc., obtained by the manufacturing method of the present invention are as desired. The items for quality inspection are not particularly limited, but examples include basic tests such as the morphology of cells and organoids, the presence or absence of cell surface marker expression, sterility tests, endotoxin tests, and evaluation of cell viability, and testing equipment appropriate for each item can be used.
[0035] In the manufacturing method of the present invention, when differentiating cells derived from induced pluripotent stem cells, the induced pluripotent stem cells and the differentiated cells derived from said induced pluripotent stem cells may be manufactured by the following manufacturing method.
[0036] The above-described manufacturing method is a method for producing iPS cells using a cell processing apparatus. The cell processing apparatus has a closed system section illustrated in Figure 9. The closed system section has a configuration in which a sealed container for supplying material (parts labeled 210 to 250 in the example shown in the figure) and a sealed chamber 100 that can be rotated for centrifugation are connected via a connecting conduit A10. In this manufacturing method, while maintaining the closed nature of the closed system section, the following steps (s1) to (s3) are carried out in this order within the same sealed chamber 100. Process (s1): A process of centrifuging blood cells from whole blood. Step (s2): A step of bringing the reprogramming factor into contact with the blood cells. Step (s3): A step of establishing iPS cells from the blood cells. Other processing steps may be added between each of the steps (s1) to (s3) described above, and between each of the steps (s1) to (s3) described above, blood cells may be transferred from the sealed chamber to other elements within the closed system and then returned to the sealed chamber. Furthermore, in response to additional processing such as quality control measurements, between each of the steps (s1) to (s3) described above, the blood cells in the process of processing may be aseptically transferred to an external sealed container, where additional filtering or measurements may be performed, and then returned to the original closed system for the next step. These additional processing may be performed manually, automatically, or semi-automatically. In any case, the main steps (s1) to (s3) of the present invention are performed automatically inside the closed system according to the commands of the control unit of the cell processing apparatus (e.g., Prodigy). The commands of the control unit are pre-set for the present invention so that steps (s1) to (s3) are performed automatically and sequentially. Through the aforementioned steps (s1) to (s3), whole blood is processed in a single sealed container (a sealed chamber for centrifugation) within a single closed system to obtain raw material blood cells, from which iPS cells are established.
[0037] (Closed system portion illustrated in Figure 9) First, we will explain the configuration of each part of the cell processing apparatus that can be used in this manufacturing method. The cell processing apparatus itself may be a conventionally known apparatus as shown in Figure 16. The cell processing apparatus has a closed system portion illustrated in Figure 9 and a mechanism portion illustrated in Figure 11. The closed system portion is attached to and detached from the mechanism portion in a disposable manner. The state in which the closed system portion is attached to the mechanism portion is illustrated in Figure 12. The mechanism portion operates automatically according to a predetermined control program (computer program) and acts on the closed system portion to automatically perform the above steps (s1) to (s3) in order.
[0038] A preferred cell processing apparatus is the CliniMACS Prodigy® manufactured by Miltenyi Biotec, as shown in Figure 16. The CliniMACS Prodigy is described in detail, for example, in International Publication No. 2020 / 040135. Hereafter, the CliniMACS Prodigy will also be referred to simply as Prodigy. The following description of the manufacturing method will refer to Prodigy as a cell processing device.
[0039] (Mechanism of the cell processing device) The mechanism includes parts other than the closed system, such as various actuators, magnetic separation devices, a control computer (including computer programs), a power supply, a gas supply source, a heat source, a display device, a support part, and a housing part. Important actuators include the pinch valve V10 and peristaltic pump F10 shown in Figures 9 and 11, and a motor (not shown) that rotates the sealed chamber 100.
[0040] The pinch valve V10 is a type of electromagnetic valve that shuts off a connecting pipe (flexible tube) in a closed system section by pressing it from the outside, and opens the connecting pipe when the pressure is released. The Peristaltic Pump F10, also known as a tube pump or peristaltic pump, is a pump that moves fluid within a connecting pipeline (flexible tube) by moving the outer pressing part against the pipeline. The pinch valve V10 and peristaltic pump F10 allow for the movement of internal materials from the outside as intended, while maintaining the closed-off nature of the enclosed system.
[0041] The control unit of the mechanism (including a computer and computer program) selectively operates the necessary pinch valve V10 to open and close a specific connecting pipeline A10, operates the peristaltic pump F10 to move the necessary material or blood cells being processed within a closed system, rotates the sealed chamber 100 to perform centrifugation, and sequentially carries out each step of the manufacturing method. The computer program executed by the computer of the control unit can be pre-set to conform to the present invention by inputting or changing parameters such as the timing of opening and closing of arbitrary pinch valves, the operating period and feed rate of the peristaltic pump, and the operating period and relative centrifugal force of the sealed chamber. Therefore, by setting sealed containers for supplying the necessary materials for each step and empty sealed containers as the closed system part and executing the computer program under the pre-set conditions, the steps of the novel manufacturing method according to the present invention are automatically carried out sequentially. Furthermore, the execution of the computer program (i.e., the operation of Prodigy) can be temporarily stopped by pre-settings or by inputting a stop command such as a stop switch, and can be restarted at will. Therefore, manual processes (such as sampling for quality control or filtering) can be added during or between each process.
[0042] (Closed system section: Sealed container for material supply) The number of sealed containers for supplying materials may be equal to the number of types of materials used in processing the cells to be manufactured. The number of materials used may differ from the number of sealed containers if the materials are pre-mixed. Furthermore, multiple sealed containers containing the same material may be prepared for large quantities of material needed. The capacity of the sealed containers is not particularly limited and varies depending on the material, but is generally around 20-3000 ml.
[0043] In Figure 9, as an example for illustrative purposes, a sealed container 210 containing whole blood diluted with PBS (for example, a mixture of whole blood and PBS in a 1:1 volume ratio), a sealed container 220 containing liquid culture medium, a sealed container 230 containing centrifugation medium, a sealed container 240 containing a fluid containing initialization factors, and an empty sealed container 250 used as a temporary storage location for materials are each connected to the sealed chamber 100 via connecting conduits. However, the example in Figure 9 is not limited to this; sealed containers containing materials according to the process may be connected as part of the closed system for supply. Each material will be described later.
[0044] The configuration of the sealed container for supplying materials is not particularly limited, and can refer to sealed containers used in conventional cell processing devices such as Prodigy. Preferred examples include flexible bags made of flexible film or flexible sheets. The flexible film is a film that has enough flexibility to deform according to the amount of contents in the bag. The flexible film may also be gas permeable, allowing O2 and CO2 necessary for cell culture to pass through. In Prodigy, the required number of bags, which are sealed containers for supplying materials, are suspended from the support column B10 shown in Figure 11, resulting in the usage state shown in Figure 12.
[0045] (Closed system section: A sealed chamber with a centrifugal separation function) The sealed chamber 100 is configured to allow rotation for centrifugal separation while maintaining a closed system, that is, while the connecting conduit A10 remains connected, and even while material is flowing in or out. The centrifugal separation may be based on density gradient centrifugation. To perform density gradient centrifugation, the necessary centrifugal medium (described later) may be supplied from a sealed container for material supply to the sealed chamber.
[0046] The materials used to fabricate the sealed chamber are not particularly limited, but for example, commonly used materials such as glass, polystyrene, polycarbonate, polyethylene terephthalate, polyvinylidene fluoride, polyethylene, polypropylene, polyethylene methacrylate, and other polymer compounds, ceramics, and metals can be used.
[0047] (Mechanism of centrifugal separation) Figure 10 is a schematic diagram illustrating the centrifugal separation process within a Prodigy sealed chamber. The shape determined by the side walls (inner walls) surrounding the internal space of the sealed chamber is generally cylindrical. A support column is located in the center of the internal space, and a flow path is provided inside. As shown in Figure 9, the geometric rotational centerline y1 of the cylindrical shape coincides with the central axis of rotational motion during centrifugal separation of the sealed chamber. The base area of the cylindrical shape is 90-200 cm². 2 There are variations, and examples of measured inner diameters of the cylindrical shape (inner diameter of the sealed chamber) are approximately 12 cm and 14 cm, but are not limited to these. In centrifugal separation, the relative centrifugal force acting on the contents inside the sealed chamber is 100 to 500 G, and the relative centrifugal force used in the example is 400 G.
[0048] As shown in Figures 10(a) and (b), an opening 100a for material inflow and outflow is provided at the bottom of the sealed chamber 100, located a predetermined distance from the side wall towards the center. This opening 100a is connected to the external connecting pipeline shown in Figure 9 through a flow path 110 that passes through the bottom and the central support column 120. On the other hand, an opening 100b for material outflow is provided at the upper side of the sealed chamber 100, located near the side wall. This opening 100b is connected to the external connecting pipeline shown in Figure 9 through an upper flow path 130.
[0049] In centrifugation, first, as shown in Figure 10(a), the substance to be centrifuged (such as whole blood) K10 and, if necessary, a centrifugation medium are injected into the sealed chamber 100 through the channel 110. Next, as shown in Figure 10(b), the entire sealed chamber rotates at the rotational speed required for centrifugation. In density gradient centrifugation, this rotation separates the substance in the sealed chamber into multiple fractions of different densities. In the example in Figure 10(b), the substances are separated from the inside outwards into fraction K11, which mainly contains the centrifugation medium; fraction K12, which mainly contains peripheral blood mononuclear cells (PBMCs); and fraction K13, which mainly contains red blood cells. While maintaining this separation (i.e., while the sealed chamber continues to rotate), fraction K11 is discharged from the bottom opening 100a, fraction K13 is discharged from the top opening 100b, and fraction K12, which mainly contains PBMCs, remains in the sealed chamber, completing the desired centrifugation (isolation). In this way, the desired fraction, which has been centrifuged, can be left inside the sealed chamber, while other fractions can be discharged outside the sealed chamber. Alternatively, if necessary, only the desired fraction, which has been centrifuged, can be discharged outside the sealed chamber. These processes are carried out automatically by the operation of the pinch valve, peristaltic pump, and sealed chamber drive motor in response to commands from a pre-set control unit.
[0050] The capacity of the sealed chamber is not particularly limited, but a capacity of approximately 300 to 700 ml is preferable. Alternatively, sealed chambers of various capacities may be prepared depending on the scale of processing, such as a regular-sized sealed chamber with a capacity of 400 ml and a large-sized sealed chamber with a capacity of 600 ml.
[0051] The amount of fluid centrifuged at one time in the sealed chamber is not particularly limited, but is approximately 10 to 250 ml, preferably 30 to 130 ml.
[0052] (Closed system section: connecting conduit) In Prodigy, given the use of the pinch valve and peristaltic pump described above, the pipe members constituting the connecting pipeline A10 are preferably tubes made of soft materials (silicone, polyvinyl chloride, etc.). The connecting pipeline may also include pipe members made of hard materials in parts such as joints.
[0053] (Closed or airtight) In closed systems, sealed containers, and sealed chambers, the internal seal or airtightness refers not only to a state where the interior is kept airtight or liquid-tight, but also to a state where the interior is isolated from the outside world to the extent that microorganisms and viruses cannot enter from the outside, i.e., to the extent that internal sterility is maintained. For example, a sealed chamber equipped with a porous filter (for example, with a pore size of about 0.2 μm or less, especially about 0.1 to 0.2 μm) that prevents bacteria and viruses from passing through but allows fluids (especially gases) to pass through, allows outside air to pass through the porous filter and into the sealed container, but prevents bacteria and viruses from entering, thus maintaining sterility within the closed system and thus possessing airtightness. Similarly, a container with a gas-permeable membrane on its walls, which prevents bacteria and viruses from passing through but allows O2 gas molecules and CO2 gas molecules to pass through, also possesses airtightness. Therefore, a "closed system" is similarly not only a system that is closed in an airtight or liquid-tight manner, but also a system in which the interior is isolated from the outside world to the extent that microorganisms and viruses cannot enter from the outside.
[0054] Next, we will explain the iPS cells to be manufactured, and the raw materials and ingredients necessary for their production.
[0055] (induced pluripotent stem cells) In this specification, "induced pluripotent stem cell (iPS cell)" refers to cells obtained by reprogramming mammalian somatic cells or undifferentiated stem cells by introducing reprogramming factors. Induced pluripotent stem cells have the ability to differentiate into various tissues and cells with different forms and functions in the living body, and to differentiate into any lineage of the three germ layers (endoderm, mesoderm, and ectoderm).
[0056] In this specification, iPS cells may be patient-derived cells. Generating iPS cells from patient-derived somatic cells and using them for clinical treatment can be an effective means of minimizing the risk of rejection.
[0057] This manufacturing method can be used for the production of any iPS cells currently available.
[0058] In this specification, induced pluripotent stem cells may be cells derived from patients with hereditary diseases. Cells differentiated from pluripotent stem cells derived from patients with hereditary diseases can serve as disease models that reflect the pathogenesis of the disease, and are therefore suitable for screening for therapeutic or preventive drugs for the disease. Alternatively, by repairing the genes of pluripotent stem cells derived from patients with hereditary diseases using genome editing with a CRISPR-Cas system or the like, and then differentiating them into target cells, it is possible to use these cells as therapeutic agents for the disease.
[0059] (Whole blood) In this specification, "whole blood" means blood itself collected from a subject such as a human, in which blood cells and other components have not been separated. In this specification, "whole blood" may also include whole blood diluted by mixing with an appropriate buffer solution, or whole blood to which additives such as blood coagulation inhibitors (e.g., heparin, EDTA, citrate, etc.) or protease inhibitors have been added. The buffer solution used to dilute the whole blood is not particularly limited as long as it does not affect the blood cell components in the whole blood in a way such as hemolysis, but examples include phosphate buffer (PBS) and physiological saline.
[0060] (Whole blood supply) In the present invention, the amount of whole blood supplied to the sealed chamber is not particularly limited, but is approximately 5 to 100 ml, preferably 10 to 50 ml, more preferably 10 to 40 ml, and even more preferably 10 to 20 ml. The whole blood may be placed in a sealed container for material supply in its collected state and sent to the sealed chamber, or it may be diluted with a buffer solution as described above and then placed in a sealed container for material supply and sent to the sealed chamber.
[0061] (blood cells) In this specification, "blood cells" refers to all cells in the process from hematopoietic stem cells through hematopoietic progenitor cells (including pluripotent hematopoietic progenitor cells and unipotent hematopoietic progenitor cells) to ultimately functional blood cells. Examples of blood cells include peripheral blood mononuclear cells (PBMCs) and umbilical cord blood mononuclear cells (CBMNCs).
[0062] (Lymphatic cells) In this specification, "lymphoid cells" refers to cells including CD34-positive hematopoietic progenitor cells (lymphoid progenitor cells) and their differentiated cells such as B cells, NK cells, and T cells.
[0063] In this specification, the origin of the blood cells is not particularly limited, and the origin of the blood cells is preferably human.
[0064] In this specification, unless otherwise specified, "cell" includes "cell population." A cell population may consist of one type of cell or two or more types of cells.
[0065] In this specification, "processing" cells means subjecting them to treatments such as cell culture, dilution of cell-containing solutions, cell washing, and separation of target cells from cell-containing solutions. It also means subjecting cells to treatments such as artificial proliferation and differentiation, cell line formation, cell activation, modification of biological properties, combination with non-cellular components, or genetic engineering modifications.
[0066] (Liquid culture medium) Liquid culture media delivered from sealed containers can be used not only for cell culture but also for various purposes in the manufacturing process, such as cell washing and dilution of drug solutions. Examples of liquid culture media that can be used in this invention include the following:
[0067] The liquid culture medium is not particularly limited, but Essential8 medium (CTS TM Essential 8TM Medium, Essential 8 TM Medium, Essential 8 TM Flex Medium, Essential 6 TM Medium) (Thermo Fisher Scientific), StemFit (registered trademark) AK02 medium (Ajinomoto Co., Inc.), StemFit (registered trademark) AK03 medium (Ajinomoto Co., Inc.), StemFit (registered trademark) Basic03 medium, CTS (registered trademark) KnockOut SR XenoFree Medium (Gibco), mTeSR1 medium, TeSR1 medium (Stem Cell Technologies), Iscove's modified Dulbecco's medium (GE Healthcare), Improved MEM (Thermo Fisher Scientific), and the like. These media can also be used for culture under feeder-free and xeno-free conditions. Further examples include, but are not limited to, MSCBM-CD, MSCGM-CD (both from Lonza), and mixtures thereof.
[0068] If necessary, physiologically active substances, nutrient factors and the like necessary for cell survival or proliferation can be added to the medium.
[0069] Furthermore, antibiotics such as kanamycin, streptomycin, penicillin or hygromycin may be added to the medium as needed.
[0070] As used herein, the medium may or may not use known serum.
[0071] As used herein, the medium, similarly to serum, may or may not contain a serum substitute.
[0072] (Scaffold Material) In this specification, "scaffold material" means a material or substrate that functions as a scaffold for cells in cell culture. Scaffold materials are not particularly limited as long as they can be used in adherent culture or suspension culture using scaffold materials (in other words, they may be free in the culture medium), but examples include those containing or made of synthetic resins, or those made of flexible materials such as collagen. Microcarriers may also be used as scaffold materials. Furthermore, as an example, scaffold materials may contain atelocollagen. Scaffold materials may be manufactured by known methods, or commercially available products may be used. Examples of commercially available products include Cytodex-1 (manufactured by GE Healthcare) and Corning® low-concentration Synthemax® II microcarriers (manufactured by Corning).
[0073] Furthermore, the scaffold material may contain or consist of an extracellular matrix, such as a basement membrane preparation (e.g., Matrigel (Corning), Geltrex matrix (Thermo Fisher Scientific), etc.), fibronectin, laminin or its fragments, entactin, collagen, gelatin, vitronectin, etc., or a combination thereof. The extracellular matrix as exemplified may be a natural product, an artificially synthesized product using genetic engineering technology, or a fragment cleaved with restriction enzymes, or a synthetic protein or synthetic peptide based on these biologically derived substances.
[0074] Laminin is a heterotrimeric molecule composed of α, β, and γ chains, and is an extracellular matrix protein with isoforms that differ in the composition of the subunit chains. Specifically, laminin has approximately 15 isoforms, which are combinations of heterotrimers of 5 α chains, 4 β chains, and 3 γ chains. The name of the laminin is determined by combining the numbers of the α chains (α1 to α5), β chains (β1 to β4), and γ chains (γ1 to γ3). For example, laminin with the combination of α5, β1, and γ1 chains is called laminin-511. Laminin may be a natural product, artificially synthesized using genetic engineering or other technologies, or it may be a synthetic protein or synthetic peptide based on laminin.
[0075] The laminins or fragments thereof used in the present invention include laminin-111 or a fragment containing its E8 region (e.g., iMatrix-111), laminin-211 or a fragment containing its E8 region (e.g., iMatrix-211), laminin-121 or a fragment containing its E8 region, laminin-221 or a fragment containing its E8 region (e.g., iMatrix-221), laminin-332 or a fragment containing its E8 region (e.g., iMatrix-332), laminin-3A11 or a fragment containing its E8 region, laminin-411 or a fragment containing its E8 region (e.g., iMatrix-411), laminin-421 or a fragment containing its E8 region, and laminin-511 or a fragment containing its E8 region (e.g., iMatrix-511, iMatrix-511). Examples include fragments containing laminin-521 or its E8 region, laminin-213 or its E8 region, laminin-423 or its E8 region, laminin-523 or its E8 region, laminin-212 / 222 or its E8 region, laminin-522 or its E8 region, and the like.
[0076] Vitronectin may be a natural product, artificially synthesized using genetic engineering technology, or a synthetic protein or peptide based on the aforementioned vitronectin. Due to their availability, commercially available products include, for example, Vitronectin, derived from human plasma (manufactured by Sigma-Aldrich), Vitronectin (20-398aa), human, recombinant, solution (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.), and Vitronectin (VTN-N) Recombinant Human Protein, Truncated (manufactured by Gibco).
[0077] Fibronectin may be a natural product, artificially synthesized using genetic engineering technology, or a synthetic protein or peptide based on fibronectin. Due to its availability, commercially available products include, for example, fibronectin solution, human plasma-derived fibronectin (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.), and Retronectin® (manufactured by Takara Bio Inc.).
[0078] The type of collagen used is not particularly limited, but for example, type I collagen or type IV collagen can be used. The collagen may be a natural product, artificially synthesized using genetic engineering technology, or a synthetic peptide based on the aforementioned collagen. Due to their availability, commercially available products include, for example, Collagen I, Human (manufactured by Corning) and Collagen IV, Human (manufactured by Corning).
[0079] Furthermore, the scaffolding material may contain or consist of a synthetic resin and an extracellular matrix as described above. Examples of polymers (resins) used in scaffolding materials include polystyrene, polyolefin, polyethylene terephthalate, polyether, polyvinyl alcohol, polyvinyl acetal (e.g., polyvinyl butyral), polyester, poly(meth)acrylic acid ester (poly(meth)acrylate), epoxy resin, polyamide, polyimide, polyurethane, polycarbonate, cellulose, dextran, polypeptide (gelatin, etc.).
[0080] Scaffold materials containing or consisting of synthetic resin and extracellular matrix include, for example, International Publication No. 2023 / 127777, JP 2022-077840, JP 2021-023287, JP 2021-003103, JP 2021-003102, JP 2021-003099, JP 2021-003062, JP 2021-003061, JP 2020-174682, JP 2019-118345, JP 2019-115323, JP 2019-115322, International Publication No. 2019 / 131982, International Publication Examples of publicly known works include those described in JP 2019 / 131981, International Publication 2019 / 131978, JP 2016-106545, JP 2015-221851, International Publication 2015 / 098919, International Publication 2009 / 099555, International Publication 2010 / 138486, International Publication 2010 / 138687, International Publication 2010 / 138702, US2011152455A1, International Publication 2011 / 014594, International Publication 2011 / 014605, International Publication 2012 / 150475, International Publication 2013 / 116432, etc.
[0081] In one embodiment, the scaffold material comprising a synthetic resin and a peptide comprises a polyvinyl acetal resin, preferably a polyvinyl butyral resin, and a cell-adhering peptide, or a poly(meth)acrylate resin (poly(meth)acrylic acid ester resin) and a cell-adhering peptide, as described in Japanese Patent Publication No. 2021-023287, Japanese Patent Publication No. 2022-077840, and International Publication No. 2023 / 127777, International Publication No. 2011 / 014594, etc. In this specification, "cell-adhering peptide" means a peptide whose cell-adhering activity has been confirmed by phage display, Sepharose bead method, or plate-coating method. The cell-adhering peptide is preferably a peptide consisting of three or more amino acids, more preferably 3 to 20 (e.g., 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19), even more preferably 3 to 15, and particularly preferably 3 to 10. The cell-adhering peptide also preferably contains an RGD sequence (Arg-Gly-Asp). A commercially available example of such a scaffolding material is Corning® Synthemax® Vitronectin Substrate (manufactured by Corning).
[0082] The method of supplying scaffolding materials to a sealed chamber or the like is not particularly limited as long as the desired cells can be processed appropriately, and the supply conditions (e.g., timing of supply, volume, etc.) and types of scaffolding materials can be appropriately set by those skilled in the art.
[0083] In one embodiment, the scaffolding material described above may be applied to the sealed chamber used in the manufacturing method of the present invention before performing at least one of steps (s1), (s2), (s3), (s4), and (s5). In another embodiment, when iMatrix is used as the scaffolding material, the scaffolding material described above may be applied to the sealed chamber by adding it to the culture medium used in at least one of steps (s1), (s2), (s3), (s4), and (s5). In yet another embodiment, the scaffolding material may be applied to the sealed chamber by adding it to the culture medium used in at least one of steps (s1), (s2), (s3), (s4), and (s5).
[0084] (Centrifugal separator) In step (s1), density gradient centrifugation is useful for separating blood cells from whole blood. In this case, the centrifugation medium for density gradient centrifugation is supplied from a sealed container for material supply to a sealed chamber. The centrifugation medium is a hydrophilic polysaccharide (Ficoll TM Examples include the following.
[0085] In the density gradient centrifugation in step (s1), whole blood (which may be diluted) and a centrifugation medium are supplied to a sealed chamber, density gradient centrifugation is performed, and the fraction containing blood cells remains in the sealed chamber.
[0086] (initialization factor) In step (s2), a pinch valve and a peristaltic pump are activated to deliver a fluid containing the initialization factor from a sealed container for material supply to a sealed chamber. Separated blood cells are present in the sealed chamber due to step (s1), and the initialization factor comes into contact with these blood cells. When the initialization factor comes into contact with the blood cells, the sealed chamber may be stationary, rotated, or a combination of both.
[0087] In this specification, examples of "initialization factors" include Oct3 / 4, Sox2, Sox1, Sox3, Sox15, Sox17, Klf4, Klf2, c-Myc, N-Myc, L-Myc, Nanog, Lin28, Fbx15, ERas, ECAT15-2, Tcl1, beta-catenin, Lin28b, Sall1, Sall4, ESrrb, Nr5a2, Tbx3, or Glis1. These initialization factors may be used individually or in combination. Any known combination of initialization factors can be used.
[0088] The reprogramming factor introduced into somatic cells may be in the form of a protein, a nucleic acid (RNA or DNA) encoding the protein, or an expression vector containing the nucleic acid. When the reprogramming factor is introduced in the form of RNA, the immunogenic RNA introduced into the cell may activate the cell's defense mechanism; therefore, RNA that evades this defense mechanism may be introduced into the somatic cell.
[0089] Examples of expression vectors include viral vectors such as retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, herpesviruses, and Sendai viruses, as well as plasmid vectors, episomal vectors, artificial chromosome vectors, and transposon vectors (piggyBac, piggyBat, TolII).
[0090] The introduction of nucleic acids, expression vectors containing said nucleic acids, or proteins (e.g., reprogramming factors) into cells can be carried out by various known methods. Examples of such methods include calcium phosphate-mediated transfection, electroporation, liposome transfection, lipofection, gene guns, microinjection, viral vector methods, virus-like particle methods, Agrobacterium methods, agroinfiltration methods, PEG-calcium methods, sonoporation methods, and lipid nanoparticle methods.
[0091] (Materials for constructing a sealed chamber and cell culture) The Prodigy sealed chamber material includes a portion made of polycarbonate resin. The main parts of the actual sealed chamber's internal space (internal side walls and internal bottom) are made of polycarbonate resin, and as a result, these surfaces are non-adherent to cells and unsuitable for culturing iPS cells, which are adherent cells (adherent culture using the inner walls). Therefore, in a preferred embodiment of the manufacturing method, a suitable scaffold material is supplied to the sealed chamber, and steps (s2) and (s3) are carried out in the presence of the scaffold material. Alternatively, the scaffold material may be supplied to the sealed chamber at step (s2) to simplify the coating process.
[0092] In a preferred embodiment of the manufacturing method, a scaffolding material is adhered to the inner wall surface of a sealed chamber. This is preferable because it enables adhesive culture even if the inner wall surface of the sealed chamber is made of polycarbonate resin. Examples of such scaffolding materials include those containing laminin fragments (e.g., laminin-511, laminin-332, etc.), cell-adhering peptides and polyvinyl acetal resin (e.g., polyvinyl butyral resin, etc.), and those containing cell-adhering peptides and poly(meth)acrylate resin. In a preferred embodiment, the cell-adhering peptide contains an RGD sequence (Arg-Gly-Asp).
[0093] The aforementioned scaffolding material supply method involves dissolving powdered Synthemax 1 vial (10 ml) in 10 ml of sterile water in a safety cabinet, sealing it in a sealed container, aseptically sealing it, removing the sealed container from the safety cabinet, aseptically connecting it to a Prodigy, and pumping it into a sealed chamber using a peristaltic pump. The container is then kept at 22°C overnight for pre-coating. When using a small amount of scaffolding material, it may be mixed with PBS or sterile water to facilitate supply. Liquid iMatrix can be supplied in its undiluted form.
[0094] (Other substances to be supplied) In addition to the materials mentioned above, other substances necessary for cell processing may be added as appropriate. The added materials can be housed in sealed containers or the like and connected to a sealed chamber, similar to the materials mentioned above. Other materials that may be added include, for example, liquids, powders, additives, release agents, cryoprotection solutions, and CO2.
[0095] (Regarding the process of establishing iPS cells (s3)) Step (s3) in the manufacturing method of the present invention is a step of culturing blood cells in a liquid medium to establish iPS cells, and the establishment of induced pluripotent stem cells can be appropriately confirmed by the expression of reprogramming factors introduced by known methods (e.g., Oct3 / 4, SOX2, Nanog, TRA-1-60, TRA-1-81, SSEA3, SSEA4, alkaline phosphatase, etc.). The period for performing step (s3) is not particularly limited as long as iPS cells are established, but typically it is, for example, 10 days or more, and 14 days or more is preferred. There is no particular upper limit, but typically it is 30 days or less, and 40 days or less is preferred.
[0096] A preferred example of Prodigy operation for carrying out steps (s1) to (s3) is as follows: (e1) to (e15). (e1) In Figure 9, diluted whole blood (for example, 20 ml of whole blood diluted with 30 ml of phosphate-buffered saline (PBS)) contained in a sealed container 210 for material supply is sent to a sealed chamber 100. (e2) Ficoll, a density gradient centrifugal separation medium contained in a sealed container 230 for material supply, is sent to a sealed chamber 100. (e3) The sealed chamber 100 is rotated, density gradient centrifugation is performed, and a fraction mainly containing PBMC remains in the sealed chamber. (e4) The fraction mainly containing the PBMC is sent to an empty sealed container 250. The connecting conduit to the sealed container 250 is sealed by heat fusion and the sealed container 250 is aseptically cut from the Prodigy. (e5) The sealed container 250 is aseptically joined to another sealed container containing a filter, and the PBMC contained in the sealed container 250 is poured into the other sealed container containing the filter through the top opening, so that the debris (clumps of unwanted cellular material) is removed through the filter inside the sealed container. (e6) A portion of the fraction mainly containing the PBMCs is manually sampled, stained with trypan blue, and the number of cells is measured using a cell counter. Steps (e4) to (e6) are not essential steps for the present invention, but are preferable to perform. (e7) If applicable, at this point scaffolding material (such as Synthemax) is supplied from the sealed container for material supply into the sealed chamber 100, and the inner wall surface of the sealed chamber is coated with the scaffolding material. (e8) The sealed container with the filter built in is manually and aseptically connected to the closed system section, the fraction mainly containing the PBMC is returned to the sealed chamber 100 by a peristaltic pump, and a fluid containing the Sendai virus vector as an initialization factor is sent from the sealed container 240 for material supply to the sealed chamber 100. (e9) The Sendai virus vector comes into contact with the PBMC in a sealed chamber (2 hours). (e10) Liquid culture medium is added to the sealed chamber from a sealed container 220 for material supply. (e11) A portion of the contents inside the sealed chamber is manually sampled and the number of cells is counted. This step (e11) is not essential to the present invention, but it is a preferred step to perform. (e12) The liquid culture medium in the sealed chamber is reduced, cytokines are added, and cell culture is started (establishment of iPS cells is initiated). (e13) Depending on the circumstances, scaffolding material is supplied from the sealed container for material supply to the sealed chamber 100 at this point and mixed by the rotation of the sealed chamber (if the inner wall surface of the sealed chamber is to be coated, the mixing conditions are 37°C and 30 to 60 minutes). (e14) Replace or add liquid culture medium in the sealed chamber. (e15) Colonies (in the case of adherent culture) or spheroids (in the case of suspension culture) are observed 14 to 21 days after the start of the cell culture (start of iPS cell establishment).
[0097] (Expanded culture) In this manufacturing method, after the step of establishing iPS cells (s3) described above, a step (s4) of expanding the iPS cell culture in the sealed chamber may be further included, from the viewpoint of iPS cell yield. Step (s4) is carried out while maintaining the closed nature of the closed system, similar to steps (s1) to (s3). The expansion culture of iPS cells in the sealed chamber can be carried out by supplying a culture medium suitable for expansion culture to the sealed chamber. The culture medium used in step (s4) can be appropriately selected by a person skilled in the art from the liquid culture media described above. In one embodiment, if the intention is to expand the culture of established induced pluripotent stem cells, an undifferentiated maintenance factor may be added. In this specification, "undifferentiated maintenance factor" means a substance that has the effect of suppressing the differentiation of induced pluripotent stem cells, and is not particularly limited as long as it is such a substance. Examples of undifferentiated maintenance factors commonly used by a person skilled in the art include bFGF, FGF2, FGF4, FGF8, EGF, Nodal, ActivinA, ActivinB, TGFβ1, and TGFβ2. The undifferentiated maintenance factors used in this invention are preferably isolated. "Isolation" means that the target component and factors other than cells have been removed, thus moving away from their naturally occurring state.
[0098] In step (s4), the number of expansion cultures performed is not particularly limited as long as the desired number of iPS cells can be obtained, but in normal processing operations, 1 to 5 times is preferable, and more preferably 2 to 5 times. The duration of step (s4) is not particularly limited as long as the desired number of iPS cells can be obtained, but typically it is, for example, 1 to 40 days, 3 to 20 days, or 5 to 10 days. If the Sendai virus vector used for reprogramming contains a GFP marker, it is desirable to continue expansion culture until the marker disappears.
[0099] (Magnetic separation process) In the manufacturing method of the present invention, if the blood cells to be separated in step (s1) are the lymphoid cells described above (e.g., CD34-positive cells (more specifically, hematopoietic progenitor cells)), the required lymphoid cells can be isolated from PBMCs by centrifuging the PBMCs from whole blood and then adding a magnetic separation step. In this case, as shown in Figure 13, a magnetic separation column 300 connected to the sealed chamber 100 via a connecting conduit A10 is used as part of the configuration of the closed system. The magnetic separation column 300 is mounted on the magnetic separation unit M10 in the mechanism shown in Figure 11. In Figure 13, the lymphoid cells to be separated are labeled with magnetic beads in the sealed chamber 100. In the example in Figure 13, the magnetic beads are sent from a sealed container 260 for material supply to the sealed chamber. When the suspension containing the lymphoid cells (with magnetic beads) is transferred from the sealed container 100 into the magnetic separation column 300, only the lymphoid cells (with magnetic beads) are trapped (i.e., magnetically separated) within the magnetic separation column 300 by the magnetic field acting from the magnetic separation unit M10. Other blood cells and foreign matter pass through the magnetic separation column 300 and are sent to a negative selection bag (not shown). Subsequently, the application of the magnetic field by the magnetic separation unit M10 is stopped, the pinch valve is switched, and the lymphoid cells (with magnetic beads) trapped in the magnetic separation column 300 are released and sent to a positive selection bag 310. Then, the pinch valve is switched again, and the lymphoid cells (with magnetic beads) in the positive selection bag 310 are returned to the sealed chamber 100. The magnetic beads may be actively removed by a desorption process and used for the next step, but if they are extremely fine magnetic beads of about 50 nm, for example, such extremely fine magnetic beads will naturally detach from the lymphoid cells by continuing the processing in the next step (s2).
[0100] (Magnetic beads, detachment of magnetic beads) The magnetic separation method itself and the necessary materials can be set and selected as appropriate by referring to known technologies. Magnetic beads include CliniMACS CD1c (BDCA-1) GMP Biotin, CliniMACS CD3 GMP MicroBeads, CliniMACS CD4 GMP MicroBeads, CliniMACS CD8 GMP MicroBeads, CliniMACS CD14 GMP MicroBeads, CliniMACS CD19 GMP MicroBeads, CliniMACS CD25 GMP MicroBeads, CliniMACS CD34 GMP MicroBeads, CliniMACS CD45RA GMP MicroBeads, CliniMACS Prodigy CD45RA MicroBeads, CliniMACS Anti-Biotin GMP Examples include MicroBeads, CliniMACS TCRα / β GMP Biotin, and CliniMACS TCRα / β GMP Kit. One method for removing magnetic beads is to allow them to detach naturally during the cell culture process. The materials for modification with magnetic beads and for de-modification may be appropriately supplied to the sealed chamber from additional sealed material supply containers as needed.
[0101] A preferred example of Prodigy operation when steps (s1) to (s2) involve magnetic separation of lymphoid cells is as follows, and is performed according to Prodigy's magnetic separation program "T cell transduction process". (f1) In Figure 9, 50 ml of diluted whole blood (20 ml of whole blood diluted with 30 ml of phosphate-buffered saline (PBS)) contained in a sealed container 210 for material supply is sent to a sealed chamber 100. (f2) Ficoll, a density gradient centrifugal medium contained in a sealed container 230 for material supply. TM 150 ml is sent to the sealed chamber 100. (f3) The sealed chamber 100 rotates, and density gradient centrifugation is performed, leaving a fraction mainly containing PBMC in the sealed chamber. (f4) The fraction mainly containing the PBMC is sent to an empty sealed container 250. (f5) The fraction is sent to a labeling column (not shown) in Prodigy, where lymphoid cells in PBMCs are labeled with magnetic beads. (f6) Lymphoid cells (with magnetic beads) are returned to the sealed chamber and incubated. (f7) In a sealed chamber, cleaning is performed to remove excess magnetic beads. (f8) Lymphoid cells (with magnetic beads) are sent to a magnetic separation column and magnetically trapped within the column. (f9) Washed within the magnetic separation column. (f10) Magnetic application to the magnetic separation unit is stopped. (f11) Lymphoid cells (with magnetic beads) are returned to the sealed chamber 100. Because the magnetic beads are extremely small, they are used directly in the next initialization process. (f12) A portion is manually sampled and stained with trypan blue (filtered from Gibco Trypan Blue Stain (0.4%), 15250-061), and the number of cells is measured using a cell counter. This step (f12) is not essential to the present invention, but it is a preferred step to perform. (f13) Depending on the case, at this point scaffolding material (such as Synthemax) is supplied from the sealed container for material supply into the sealed chamber 100, and the inner wall surface of the sealed chamber is coated with the scaffolding material. (f14) A fluid containing the Sendai virus vector as an initialization factor is sent from a sealed container for material supply to a sealed chamber 100. (f15) In a sealed chamber, the Sendai virus vector is brought into contact with lymphoid cells (with magnetic beads) for 2 hours. (f16) Liquid culture medium is added to the sealed chamber from a sealed container for material supply. (f17) A portion of the contents inside the sealed chamber is sampled and the number of cells is measured. (f18) The liquid culture medium in the sealed chamber is reduced, cytokines are added, and cell culture is started (iPS cell establishment is initiated). (f19) Depending on the circumstances, at this point scaffolding material is supplied from a sealed container for material supply into a sealed chamber and mixed (if coating is to be performed on the inner wall surface of the sealed chamber, the mixing conditions are, for example, 37°C and 30 to 60 minutes). (f20) Replace or add liquid culture medium in the sealed chamber. (f21) Colonies (in the case of adherent culture) or spheroids (in the case of suspension culture) are observed 14 to 21 days after the start of the cell culture (start of iPS cell establishment).
[0102] (Quality assessment of iPS cells) The quality of the obtained iPS cells may be evaluated by a known method after step (s3) or after step (s4) of the manufacturing method of the present invention.
[0103] (Method for producing differentiated cells) Next, the method for producing differentiated cells according to the present invention will be described. The method for producing differentiated cells comprises steps (s1) to (s3) of the iPS cell production method according to the present invention described above, and further includes a step (s5) of inducing differentiation of iPS cells after these production methods. Step (s5) is carried out while maintaining the closed nature of the closed system portion, similar to steps (s1) to (s3) and step (s4). In step (s5), the materials necessary for differentiation induction are supplied from a sealed container (not shown) for material supply into the sealed chamber, and step (s5) is carried out within the sealed chamber. In Figures 9 and 13, the illustration of the sealed container for supplying the materials necessary for differentiation induction is omitted.
[0104] The aforementioned step (s5) may be performed after step (s3) in the method for producing iPS cells according to the present invention, without performing the step (s4) of expanding the culture of iPS cells, or it may be performed after step (s3) and after performing the step (s4) of expanding the culture of iPS cells.
[0105] In one embodiment, the cells or organoids (target cells or organoids) obtained by differentiating induced pluripotent stem cells are neural crest cells, neural progenitor cells, nerve cells, cerebral cortical organoids, hematopoietic progenitor cells, platelets, T cells, or cardiomyocytes.
[0106] (Substance that induces differentiation of iPS cells) In this specification, "differentiation-inducing substance" means a substance that can induce differentiation from induced pluripotent stem cells into the differentiated cells or organoids described above. The differentiation-inducing substance may be a substance that is already known, or it may be appropriately selected from those commonly used to induce differentiation of desired differentiated cells or organoids. Specifically, the substances described below are examples.
[0107] The fluid used as a medium for containing the reprogramming factors, undifferentiated maintenance factors, and differentiation-inducing substances is not particularly limited, but preferred examples include buffer solutions, culture media, and cryoprotective agents such as dimethyl sulfoxide (DMSO) and glycerin.
[0108] (differentiation induction method) In the manufacturing method of the present invention, known methods can be used for the differentiation induction method to obtain the target cells or organoids. For example, differentiation induction from pluripotent stem cells to neural crest cells can be carried out by methods such as those described in Fukuta M. et al., PLoS One, 2014, 9(12): e112291 or Kamiya D, et al., NPJ Regen Med., 2022 Sep 15;7(1):47. Specifically, pluripotent stem cells can be differentiated into neural crest cells by seeding them in a culture vessel and performing adherent culture (or suspension culture using a scaffolding material), followed by adherent culture (or suspension culture using a scaffolding material) in a medium containing a TGFβ inhibitor and a GSK3β inhibitor.
[0109] Neural crest cells can also be used to produce cells such as mesenchymal stem cells, neural progenitor cells, neurons, glial cells, osteocytes, chondrocytes, corneal cells, and melanocytes. For example, differentiation induction into these cells can be carried out based on methods such as those described in Fukuta M. et al., PLoS One, 2014, 9(12): e112291, Horikiri T. et al., PLoS One, 2017, 12(1): e0170342, and Kamiya D, et al., NPJ Regen Med., 2022 Sep 15;7(1):47. Specifically, for example, neural crest cells can be seeded on a plate coated with fibronectin and N-2 Supplementary fertilizer can be used. Neural progenitor cells and neurons can be obtained by replacing the medium with DMEM / F12 supplemented with nt, BDNF, GDNF, NT-3, and NGF, and culturing it at 37°C under 5% CO2 for approximately 14 days. Alternatively, neural crest cells can be seeded on a plate, cultured for 1 day in CDM medium containing SB431542 and CHIR99021, then replaced with Neurobasal medium supplemented with B-27 Supplement, N-2 Supplement, L-glutamine, Penicillin / Streptomycin, BDNF, GDNF, NT-3, and NGF, and cultured at 37°C under 5% CO2 for approximately 35 days to obtain neural progenitor cells and neurons.
[0110] Furthermore, differentiation induction into mesenchymal stromal cells can be performed using methods such as the following: Seed neural crest cells in a culture vessel and cultured for 1 day in CDM medium containing SB431542 and CHIR99021. After 1 day, the medium is replaced with αMEM containing FBS. Mesenchymal stromal cells can be obtained approximately 14 days after the start of differentiation induction.
[0111] Examples of methods for differentiating pluripotent stem cells into T cells include a method comprising (1) differentiating pluripotent stem cells into hematopoietic progenitor cells, and (2) differentiating the hematopoietic progenitor cells into T cells. Step (1) may be a step of culturing pluripotent stem cells in an induction medium for hematopoietic progenitor cells, as described in, for example, WO2013 / 075222, WO2016 / 076415, Liu S. et al., Cytotherapy, 17 (2015); 344-358. Step (2) may be a step of (2-1) inducing CD4 and CD8-positive T cells from hematopoietic progenitor cells, and (2-2) inducing CD8-positive T cells from CD4 and CD8-positive T cells, as described in WO2016 / 076415.
[0112] Examples of methods for inducing differentiation from pluripotent stem cells into cardiomyocytes include those described in WO2015 / 141827 and Laflamme MA and Murry CE, Nature. 473(7347):326-35 (2011). Other methods include, for example, producing cardiomyocytes by forming embryoid bodies from induced pluripotent stem cells in suspension culture, producing cardiomyocytes in the presence of a substance that suppresses BMP signaling (WO2005 / 033298), producing cardiomyocytes by sequentially adding Activin A and BMP (WO2007 / 002136), and producing cardiomyocytes in the presence of a substance that promotes activation of the canonical (classical) Wnt signaling pathway (WO2007 / 126077). Typically, marker proteins for cardiomyocytes include NKX2.5 (cardiac-specific transcription factor) and TNNT2 (troponin T), while marker proteins for cardiomyocyte progenitor cells include KDR (vascular endothelial growth factor (VEGF) receptor) and ISL1 (LIM homeodomain transcription factor).
[0113] Induction of monocyte differentiation can be performed using the method described in Di Cui., et al. Frontiers in Cell and Developmental Biology; vol 9, Article 656867 April 2021.
[0114] Furthermore, organoids can be produced using multiple types of cells. For example, in the case of liver organoids, as described in WO2013 / 047639, liver organoids can be produced by inducing liver progenitor cells (organ cells), mesenchymal stem cells, and vascular endothelial cells from pluripotent stem cells, and then culturing a mixture of these cells in suspension.
[0115] The manufacturing method of the present invention may involve culturing under feeder-free and / or xeno-free conditions for all or part of the period. From the viewpoint of clinical use, it is preferable that the differentiation induction method of the present invention be carried out under feeder-free and xeno-free conditions for the entire period.
[0116] The manufacturing method of the present invention may include a step of recovering the obtained target cells or organoids. The recovered cells may be cryopreserved using a cell cryopreservation solution. Alternatively, the cells recovered in a container may be counted using a cell counter, labeled with an antibody against a cell surface marker, and purified by flow cytometry, mass cytometry, magnetic cell separation, or the like.
[0117] In the cell production method of the present invention, undifferentiated cells may be removed as appropriate. The method for removing undifferentiated cells is not particularly limited as long as it can remove cells other than those produced by the cell production method of the present invention, and can be carried out by adding known undifferentiated cell removal agents to the culture medium (for example, Di Mao., et al. Angewandte Chemie International Edition; 9 January 2017, Ben-David, U., et al. Cell Stem Cell, 12, 167 (2013), WO2019 / 187918, JP 2016-93178, Yoshiki Nakashima, et. al., Molecular Therapy Vol. 26 No 7 July 2018, etc.).
[0118] Quality inspections may be performed as appropriate to determine whether the cells, organoids, etc., obtained by the manufacturing method of the present invention are as desired. The items for quality inspection are not particularly limited, but examples include basic tests such as the morphology of cells and organoids, the presence or absence of cell surface marker expression, sterility tests, endotoxin tests, and evaluation of cell viability, and testing equipment appropriate for each item can be used.
[0119] 2. Concentration method of the present invention The present invention also provides a method for enriching differentiated cells (hereinafter sometimes referred to as "the enrichment method of the present invention"), which includes a step of removing undifferentiated cells from a cell population comprising stem cells and differentiated cells derived from the stem cells, based on at least the difference in autofluorescence between the stem cells and the differentiated cells. In the enrichment method of the present invention, the above-mentioned difference is determined by comparing the autofluorescence intensity of the stem cells, the autofluorescence intensity of the differentiated cells, and the expression level of antigens specific to the differentiated cells. Regarding the concentration method of the present invention, all necessary details for carrying out the method shall be based on the contents of "1. Manufacturing Method of the Present Invention".
[0120] The present invention will be described in detail below with reference to examples, etc., but the present invention is not limited to these. [Examples]
[0121] The manufacturing method of the present invention was investigated as follows:
[0122] Example 1 (1) Materials and methods (Reagents, etc.) The reagents and other materials used in this example are shown in Table 1 below.
[0123] [Table 1]
[0124] (device) The equipment used in this embodiment is shown in Table 2 below.
[0125] [Table 2]
[0126] (Pre-processing) • Perform collagenase treatment starting the evening before FACS. • Carefully remove the supernatant using a pipette. Add 2 mL of PBS and wash. • Carefully remove the supernatant using a pipette. Add collagenase II at a rate of 2 mL / well. • Leave it undisturbed overnight in a CO2 incubator. The collagenase II solution was prepared by suspending 100 mg of collagenase II powder in 100 mL of HBSS(+) and sterilizing it by filtration through a 0.22 μm filter. The induced cardiomyocytes described later were obtained by differentiating human iPS cells (a hybrid of CFiS-s01 and Ff-I01s01 strains from the Kyoto University iPS Cell Research Foundation) into cardiomyocytes according to the cardiomyocyte differentiation protocol described in the research and development protocol on the Kyoto University iPS Cell Research Foundation website, with the exception of the changes made in the next paragraph. The cells used were those from day 15 onwards.
[0127] The following are the changes from the research and development-use cardiomyocyte differentiation protocol described on the Kyoto University iPS Cell Research Foundation website: - Day 0 of cardiomyocyte differentiation induction 3. Add Benzonase to TrypLE select at a concentration of 10 U / mL. 9. 2.0-6.0 x 10 6 Adjust the concentration to 2.0 mL of cells. 10. Sow 2.0 mL of seeds into the plate. - First day of culture medium change 3. Add 2.0 mL / wellsw medium. - Day 3 of culture medium change 3. Dispense double the amount of IMDM (or StemPrp) into tubes. 4. Transfer the entire volume of spheres from the plate to the tube prepared in step 3. 5. Add IMDM (or StemPrp) at a rate of 2 mL / well to the plate from which the culture medium has been removed. 6. Centrifuge the tube from step 4 at 160 xg at room temperature for 1 minute, and remove the supernatant without aspirating the spheres. 7. Collect the IMDM (or StemPrp) from the plate into the same tube. 8. Add 2 mL / well of PBS to the plate from which the culture medium has been removed. 9. Centrifuge the tube from step 7 at 160 xg at room temperature for 1 minute, and remove the supernatant without aspirating the spheres. 10. Add Differentiation Medium 2 to a total volume of 3-4 mL / well. (Guideline: 3 mL for 2.0-4.0 cells / well, 4 mL for 4.0-6.0 cells / well) 11. Remove PBS from the plate and re-seed the spheres with 3-4 mL / well. 12. Place in a low-oxygen incubator (37°C, 5% CO2, 5% O2). - 7th day of culture medium change 3. Add Differentiation Medium 3 until the total volume reaches 3-4 mL / well. (Guideline: 3 mL for 2.0-4.0 cells / well, 4 mL for 4.0-6.0 cells / well) - 9th day of culture medium change 4. Add Differentiation Medium 3 until the total volume reaches 3-4 ml / well. (Guideline: 3 mL for 2.0-4.0 cells / well, 4 mL for 4.0-6.0 cells / well)
[0128] (On the day: Induced cardiomyocytes) • Carefully remove the supernatant using a pipette. Add TrypLE select (+DNase) at a rate of 2 mL / well. • Let it stand in a CO2 incubator for 30 minutes. After separating into single cells by pipetting, collect the entire volume into a 15 mL tube. Add 6 mL (3 times the volume) of HBSS(+)(+DNase). Centrifuge at 120 × g for 5 minutes at room temperature. • After carefully removing the supernatant with an aspirator, suspend the solution in HBSS(+)(+DNase) (adjust to the recommended concentration for each cell sorter model). +DNase was treated by adding benzonase to a concentration of 10 U / mL.
[0129] (On the day: iPS cells) • Carefully remove the supernatant using an aspirator. Add 2 mL of PBS and wash. • Carefully remove the supernatant using an aspirator. Add TrypLE select (+DNase) at a rate of 1 mL / well. • Let it stand in a CO2 incubator for 5 minutes. After separating into single cells by pipetting, collect the entire volume into a 15 mL tube. Add 3 mL (3 times the amount) of HBSS(+)(+DNase). Centrifuge at 120 × g for 5 minutes at room temperature. • After carefully removing the supernatant with an aspirator, suspend the solution in HBSS(+)(+DNase) (adjust to the recommended concentration for each sorter model).
[0130] (staining) 1-5 × 10 5 Set aside a suitable number of induced cardiomyocytes in a separate tube for staining and centrifuge at 120×g at room temperature for 5 minutes. • Carefully remove the supernatant using a pipette. • Suspend in 100 μL of antibody mixture (A) and let stand at room temperature in the dark for 30 minutes. Add 900 μl of HBSS(+)(+DNase) and centrifuge at 120 × g at room temperature for 5 minutes. • Carefully remove the supernatant using a pipette. • Suspend 300-500 μl in HBSS(+)(+DNase) and analyze using FACS or similar methods.
[0131] (Antibody mixture (A)) Add the antibody to HBSS(+)(+DNase) at the following dilution ratios. x100 APC anti-human CD31 x100 Alexa Fluor 647 anti-human CD49a x100 APC anti-human CD140b (PDGFRβ) x100 PE-Cyanine7 anti-human CD172ab (SIRPαβ) x100 APC Mouse Anti-Human CD90
[0132] (FACS measurement) • Set up the FACS AriaII (cell sorter). Prepare six different plots for all possible combinations of Hoechst, Pacific Blue, BV510, and FITC. • Obtain plots by running iPS cells at a speed of approximately 1000 events / s. • Induced cardiomyocytes stained with antibodies are flowed at a rate of approximately 1000 event / s, then separated using FSCs and SSCs to determine the cell regions, and further separated using PE-Cy7 and APC to obtain plots. • A portion of unstained induced cardiomyocytes is passed through at a rate of approximately 1000 events / s to obtain a plot. From among the six types of brute-force plots, the myocardial (+) and iPS(-) regions are identified on the unstained myocardial plot, and gating is performed at the point where the separation appears best (Gate-CM). • Unstained induced myocardium is sorted using the above gate. • At the same time, sort the parts other than the myocardial gate (Gate-Others).
[0133] The following are the combinations of short-wavelength lasers and filters that can be excited by the FACS AriaII (cell sorter) mentioned above. • Hoechst: Excitation wavelength (Ex) 375 nm / Maximum fluorescence (Em) 450 nm ·Pacific Blue: Excitation wavelength (Ex) 405 nm / Maximum fluorescence (Em) 450 nm ·Brilliant Violet: Excitation wavelength (Ex) 405 nm / Maximum fluorescence (Em) 510 nm ·FITC: Excitation wavelength (Ex) 488 nm / Maximum fluorescence (Em) 530 nm
[0134] (Checking myocardial ratio) Add approximately 1 / 20 of FBS to the sorted cells and centrifuge at 300×g at room temperature for 5 minutes. • Carefully remove the supernatant using a pipette. Transfer the entire volume to a new 1.5 mL tube while adding 300 μL of 4% PFA. Let it stand at room temperature for 15 minutes. Add 900 μl of PBS and centrifuge at 800 × g at room temperature for 2 minutes. • Carefully remove the supernatant using a pipette. Add 300 μL of Perm / Wash buffer and let stand at room temperature for 10 minutes. Centrifuge at 800 × g for 2 minutes at room temperature. • Carefully remove the supernatant using a pipette. • Resuspend the sample thoroughly in 100 μL of antibody mixture (B) and let it stand at room temperature for 30 minutes. Add 900 μl of PBS and centrifuge at 800 × g at room temperature for 2 minutes. • Carefully remove the supernatant using a pipette. • Resuspend the sample in 200 μL of FACS buffer and analyze it using FACS.
[0135] (Antibody mixture (B)) Add the antibody to the Perm / Wash Buffer at the following dilution ratios. x500 Alexa Fluor(R)647 Mouse Anti-Cardiac Troponin T
[0136] (FACS buffer) • PBS (2% FBS)
[0137] (Analyzer measurement) • Set up the Spectral Cell Analyzer (analyzer). • Cells are unfolded using FSCs and SSCs, and gating is applied to the cell portion (Gate-A). • The cells from Gate-A are plotted on a histogram of AF647 (cardiac troponin T (cTNT)). • Compare the cTNT rates of Gate-CM and Gate-Others with unstained negative controls.
[0138] Table 3 shows the settings for the FACS AriaII (cell sorter).
[0139] [Table 3]
[0140] (2) Results As shown in the materials and methods described above, induced cardiomyocytes were unfolded by autofluorescence intensity (Figure 1). Similarly, iPS cells were unfolded by autofluorescence intensity (Figure 2). In addition, induced cardiomyocytes were stained with SIRPa (CD172a), CD31, CD49a, CD90b, and CD140b to identify cardiomyocyte-specific expression regions (Figure 3). Then, cardiomyocyte-specific expression regions for SIRPa(+) / CD31(-), CD49a(-), CD90b(-), and CD140b(-) were confirmed (Figure 3).
[0141] Next, a figure was created by overlaying the results from Figures 1 to 3 onto the same plot (Figure 4). Based on the created Figure 4, the gate settings to be used in the cell sorter were considered (Figure 5). Among the induced cardiomyocyte plots (gray), the combinations that seemed likely to separate the iPS cell plot (light gray) and the SIRPa plot (dark gray) with a high cardiomyocyte ratio were those developed using Ex488 / Em530 and Ex405 / Em450. Based on these results, a sorting gate was set in the SIRPa plot (dark gray) portion that did not include the iPS cell plot (light gray) but had a high cardiomyocyte ratio (Figure 5).
[0142] Furthermore, to evaluate the effectiveness of the gates set up as shown in Figure 5, the sample before sorting (left), the sample sorted by Gate-Others (center), and the sample sorted by Gate-CM (right) were stained with cardiac troponin T (cTNT), a cardiac muscle-specific marker, to confirm the myocardial percentage (Figure 6). As a result, it was confirmed that the sample sorted by Gate-CM had a higher myocardial percentage compared to the sample before sorting. Therefore, it was understood that by isolating the target differentiated cells based on the gates set up in this way, the differentiated cells can be produced simply and effectively.
[0143] Example 2 The procedure was the same as in Example 1, except that a Sony CGX10 FACS (cell sorter) was used. Since the only gate that could be excited with a violet laser on the CGX10 was Brilliant Violet 421, the induced cardiomyocytes were plotted on the autofluorescence intensity using Ex488 / Em525 and Ex405 / Em450, as in Example 1 (Figure 7, upper left). Similarly, the autofluorescence intensity of iPS cells was also plotted on the vertical axis with Ex488 / Em525 and the horizontal axis with Ex405 / Em450 (Figure 7, upper center). Furthermore, the induced cardiomyocytes were stained with SIRPa (CD172a), CD31, CD49a, CD90b, and CD140b to identify cardiomyocyte-specific expression regions (Figure 7, upper right). Furthermore, we identified myocardial-specific expression regions for SIRPa(+) / CD31(-), CD49a(-), CD90b(-), and CD140b(-) (Figure 7, upper right).
[0144] Next, a figure was created by overlaying the results from the upper part of Figure 7 onto the same plot (lower left of Figure 7). Based on the created figure, the gate settings to be used in the cell sorter were considered (lower left of Figure 7). The data was unfolded using Ex488 / Em525 and Ex405 / Em450, and it appeared that the induced cardiomyocyte plot (gray) could be separated into the iPS cell plot (light gray) and the SIRPa plot (dark gray) which had a high cardiomyocyte ratio. Based on these results, a sorting gate was set in the SIRPa plot (dark gray) which did not include the iPS cell plot (light gray) but had a high cardiomyocyte ratio (lower right of Figure 7).
[0145] Furthermore, to evaluate the effectiveness of the gate set as shown in the lower right of Figure 7, the expression levels of OCT-4, TRA-1-60, and SSEA-4 were checked. It was confirmed that the two initialization markers, OCT-4 and TRA-1-60, were decreased in the samples sorted with Gate-CM compared to the samples sorted before sorting. Therefore, it was understood that differentiated cells of the target can be produced simply and effectively by isolating them based on the gate set in this way. Since CGX10 is a closed-system sorting device, it was suggested that it may be possible to develop a fully closed-system, end-to-end process in which iPS cell-derived differentiated cells produced in the Prodigy device, which is also a closed-system, are sorted using the closed-system sorting device CGX10.
[0146] (Reference example) In the following example, steps (s1) to (s5) of the manufacturing method according to the present invention were carried out using the reagents, apparatus, and materials listed below, and the obtained iPS cells and differentiated cells (monocytes) were evaluated. The closed system portion of the Prodigy used has the same configuration as shown in Figure 9, and the main part of the sealed chamber is made of polycarbonate resin. This closed system portion was attached to the mechanism shown in Figure 11 and made operational as shown in Figure 12. The operation of Prodigy to carry out processes (s1) to (s3) is the same as steps (e1) to (e15) or steps (f1) to (f21) shown above as preferred examples of Prodigy operation. In each example, the conditions such as the materials and quantities supplied differ, but the basic operating steps of Prodigy are the same as steps (e1) to (e15) or (f1) to (f21) above. Furthermore, although the conditions such as the materials and quantities supplied to the sealed chamber differ in the expansion culture process of the established iPS cells in step (s4) and the differentiation induction process in step (s5), the basic operating method of Prodigy is the same as in (s1) to (s3).
[0147] reagent Whole blood: Peripheral blood from healthy volunteer donors. Whole blood was received the day before the experiment and stored at room temperature, protected from light, and placed horizontally. Leukocyte removal filter: Sepacell, RZ-2000N, Asahi Kasei Ficoll-Paque PLUS (GE Healthcare, Chicago, IL, USA) 2% HSA: CSL Behring Co., Ltd., Albuminer 25% Intravenous Injection 12.5 g / 50 mL HSC Brew GMP Medium:MiltenyiBiotec, 170-076-310 The six types of cytokines used for initialization SCF: Recombinant human SCF (Fujifilm Wako Pure Chemical Industries, 197-15511) TPO: Recombinant human TPO (Fujifilm Wako Pure Chemical Industries, 207-17581) Flt-3L: Recombinant human Flt3L (Fujifilm Wako Pure Chemical Industries, 061-05391) IL-6: Recombinant human IL-6 (Fujifilm Wako Pure Chemical Industries, 098-06041) IL-3: Recombinant human IL-3 (Fujifilm Wako Pure Chemical Industries, 090-05761) G-CSF: Recombinant human G-CSF (Fujifilm Wako Pure Chemical Industries, 072-06101) iMatrix-511: MATRIXOME iMatrix-332: MATRIXOME Acrylic resin containing peptides with RGD sequence Synthemax II-SC Corning, 3535, 10 mg Laminin 521: BLA-LN521-05 Human recombinant laminin 521 500μg SeV: SRV™ iPSC-4, Tokiwa Bio Co., Ltd. GFP is present. StemFit (registered trademark) AK03N: Ajinomoto Healthy Supply Co., Ltd. TrypLE: TrypLETM Select(1X) gibco, 12563-029 0.5 mmol / L-EDTA / PBS solution: Nacalai Tesque Co., Ltd. ROCK inhibitor: CultureSure 10 mmol / L Y-27632 solution, Animal-derived-free, Wako Pure Chemical Industries, 035-24593 StemSpan-AOF: Stemcell Technologies, British Columbia, Canada BMP4: 314-BP-010 VEGF: R&D Systems, Minneapolis, MN, 293-VE-050 CHIR: MiltenyiBiotec, 130-103-926 Essential 8 Medium: Gibco, A1517001 Materials Blood bag (FLEXBOY (registered trademark) BAG 50ml (LUER LOCKS, Sartorius Stedim Biotech)) Reagent bag: Miltenyi Biotec, 20mL Regent Bag, 170-076-631 Terumo Separation Bag Microbeads: CliniMACS CD34 GMP MicroBeads, Miltenyi Biotec Device Cell processing equipment: CliniMACS Prodigy, MiltenyiBiotec Sterile splicer: TERUMO TSCD-II 5% CO2 Incubator: Panasonic Healthcare Co., Ltd., MCO-170AICUVH-PJ Microscope: Olympus Corporation, inverted routine microscope, trinocular phase contrast set (precenter) CKX41 Automatic Cell Counter: Countess II, Thermo Fisher Scientific Flow cytometry: SA3800 Spectral Cell Analyzer, Sony Corporation
[0148] Example 1A (1) Installation of the tubing set The day before the SeV infection, the barcode of the Prodigy tubing set (type: TS730) was scanned, the ACC program was selected, and the operation was performed according to the instructions on the screen. In a safety cabinet, the tubing set, including the sealed chamber of the Prodigy, was manually checked for any looseness or damage during transport, tightened, and then assembled into the Prodigy.
[0149] (2) Preparation of starting material (separation of PBMCs from whole blood) In a safety cabinet, 70 mL of whole blood was aseptically filled into a blood bag by hand. 150 mL of Ficoll-Paque was then aseptically filled into a bag, and HSC Brew was aseptically filled into a bag containing 2% HSA. These bags were manually aseptically connected to the Prodigy via tubing using an aseptic conjugate and suspended from the Prodigy. On the Prodigy screen, the Density Gradient program (LP-34) under the Adherent Cell Culture program was selected, the conditions were set and entered, and the program was started. Following this program, whole blood was transferred from the blood bag to the chamber, and then Ficoll was transferred from the suspended Ficoll bag to the chamber and centrifuged to obtain PBMCs. The PBMCs were then transferred from the chamber to the bag by the same program on the Prodigy. The program was then stopped, and the PBMCs in the bag were manually aseptically conjugated into another bag with a built-in filter using an aseptic conjugate (TERUMO TSCD-II) through the top opening. Debris was then removed from the PBMCs through the filter in the bag.
[0150] (3) Incubation of PBMC The chamber was washed with 500 mL of HSC Brew according to the program. The bag containing PBMCs suspended in 2% HSA HSC Brew was detached, and the PBMCs were transferred in a safety cabinet to a cell expansion bag containing 108 μL of six cytokines ((Protocol described on the Kyoto University iPS Cell Research Foundation website: SFC (final concentration 50 ng / mL), TPO (final concentration 10 ng / mL), Fit3L (final concentration 20 ng / mL), IL-6 (final concentration 50 ng / mL), IL-3 (final concentration 20 ng / mL), G-CSF (final concentration 10 ng / mL)) in 20 mL portions). The PBMCs were cultured in a CO2 incubator. The Prodigy chamber was washed according to the program. Inside a safety cabinet, three 0.35 mL tubes (3.5 to 52.5 times the volume) of iMatrix-511 (MATRIXOME) and PBS / MgCl2 (25 mL) were manually filled into a bag, and the bag was then aseptically connected to the Prodigy. iMatrix-511 and PBS / MgCl2 were injected into the chamber, and the chamber was pre-coated overnight at 22°C.
[0151] (4)SeV infection The following day, reagent bags containing 8 mL of 2% HSA HSC brew, 0.3 mL of SeV, and 18 mL of six types of cytokines were filled into a safety cabinet and aseptically connected to the Prodigy. The bag containing the PBMCs was connected to the Prodigy. The coating solution was removed from the chamber. By setting the conditions in the Activate Shaker type 1 and Deactive Shaker modules of the Prodigy's Activity Matrix program, the PBMCs (2 mL: 5 × 10) were introduced into the chamber. 6 Infection occurred when cells were placed in a culture medium containing SeV (8 mL), shaken for 1 minute every 30 minutes, and left to stand for 2 hours (37°C).
[0152] (5)Culture After SeV infection, 2% HSA HSC Brew (10 mL) was transferred using the Prodigy program (Culture module of the Adherent Cell Culture (ACC) System) and culture was started (day 0 after establishment). On the fifth day after establishment, 200 mL of StemFit® AK03N (manufactured by Ajinomoto Healthy Supply Co., Ltd.) and 200 μl of iMatrix-511 were filled into a Terumo isolation bag in a safety cabinet. The HSC brew bag was aseptically detached from the Prodigy and the StemFit-containing bag was manually attached. 100 mL of StemFit was fed into the chamber using the Prodigy program. The Prodigy program automatically drained 50 mL of culture medium and added 20 mL of StemFit to the chamber to replace the medium. Culturing was then continued. On day 7 after establishment, 200 mL of StemFit® AK03N and 200 μL of iMatrix-511 were manually filled into a Terumo isolation bag in a safety cabinet. The StemFit-containing bag that had been previously connected to Prodigy was manually detached with a heat sealer, and a new Terumo isolation bag was connected in its place using a sterile conjugater. 100 mL of StemFit was added via feed using the Prodigy program, and after 129 mL of medium was discharged, 5 mL of StemFit was added to automatically replace the medium, and cultivation continued. From day 7 after establishment onward, medium replacement was performed automatically by the Prodigy program, which partially removed the old medium in the chamber by centrifugation and added new medium to the chamber. Medium replacement was performed every two days until day 16 after establishment.
[0153] (6) Harvest On day 19 after establishment, TrypLE was mixed 1:1 with a 0.5 mmol / L-EDTA / PBS solution. TM25 mL of Select(1X) was added to the chamber, and the chamber was allowed to stand at 39°C for 10 minutes. Cells were then detached from the chamber. The cells were seeded in a 48-well plate, and the detached cells were cultured in a 48-well plate with an appropriate amount of AK03N, a final concentration of 10 μM of ROCK inhibitor, and 1 μL of iMatrix-511. The following day, the AK03N was replaced with AK03N without the ROCK inhibitor to remove it. On day 25 after establishment, iPS cell colonies were confirmed under a microscope.
[0154] (7) Results iPS cell colonies were observed under a microscope 23 days after establishment, and 6.6 × 10⁶ cells were observed 27 days after establishment. 4 iPS cells were observed in the cells. Therefore, it was confirmed that the entire process from whole blood to PBMC isolation, SeV infection, culture, and iPS cell establishment could be carried out consistently in a closed system within a single instrument. On day 24 after establishment, the medium was changed to 500 μL / well AK03N. On day 26 after establishment, the cells were transferred from a 48-well plate to a 6-well plate, 1.3 × 10⁶ cells. 4 Cells / well were passed into one well, and all remaining cells from each well were passed into another well.
[0155] Example 7A (1) Preparation The preparation was carried out in the same manner as in Example 1A, except that the TS730 and TS520 tubing sets were checked and tightened in the safety cabinet the day before, and buffers were prepared as follows: 150 mL of Ficoll, 0.5% HSA PBS / EDTA: 60 mL of Albuminer / PBS / EDTA 3 L, and 0.5% HSA / saline: 20 mL of Albuminer / saline 1 L.
[0156] (2) Preparation of starting materials Whole blood from a volunteer donor was filtered through a leukocyte-removing filter, and the blood remaining on the filter (filter blood) was eluted with 50 ml of PBS (-) to prepare the starting material. Separation was performed in the same manner as in Example 1A, except that 500 ml of 0.5% HSA / physiological saline was used.
[0157] (3)SeV infection The same chamber used for the whole blood to PBMC separation process was employed, but the tubing set was changed from TS730 to TS520. The chamber was washed with 0.5% HSA PBS / EDTA. 1 × 10 8 The cells were subjected to infection, and SeV (MOI 5.1×10) 7 1.5 mL of ( / mL) was used, and after diluting SeV in 10 mL of StemSpan, the total volume was increased to 20 mL. The "T cell culture 3" program was started. SeV infection was performed in the same manner as in Example 1A, except for the procedure described above. 20 mL of StemSpan was added as a feed. It was concentrated, and the final chamber volume was increased to 10 mL.
[0158] (4)Culture Aside from adding 200 μL of iMatrix-511 instead of 1 mL when seeding cells on day 0 after establishment, and not adding scaffolding material on day 1 after establishment, the procedure was as follows: StemSpan, six types of cytokines, and iMatrix-511 were simultaneously placed in the chamber at a concentration of 1 μg / cm³. 2 The following preparations were made: 200 μl iMatrix and 180 μl of 6 cytokines were added to a final volume of 30 mL. 200 mL StemSpan + 200 μl iMatrix + 180 μl 6 cytokines were fed in to create a final volume of 30 mL. - Day 1 after establishment: StemFit 20 mL + iMatrix 200 μL. - Day 3 after establishment: Add 30 mL of StemFit to the chamber via feed. - Day 5 after establishment: Add 50 mL of StemFit to the chamber via feed. - On days 7, 9, 12, 14, 16, 19, 21, and 23 after establishment: The StemFit medium was replaced by removing 50 mL and adding 50 mL, so that the culture solution in the chamber was adjusted to 130 mL. The medium was automatically replaced by the Prodigy program on days 7, 9, and 11 after establishment. From day 15 after establishment onwards, the medium was replaced manually.
[0159] (5) Harvesting Without detaching the cells from the chamber, the entire chamber was aseptically removed from the Prodigy on day 15 after establishment, and the cells were observed under a microscope.
[0160] (6) Results When observed under a microscope on day 29 after establishment, formation of spheroids in the chamber was observed. When counted with a tally counter or a counter, there were approximately 86 spheroids on day 29 after establishment, and the number of live cells was 6.98×10 6 cells as counted.
[0161] Example 9A (1) Isolation of PBMCs from whole blood, SeV infection, and culture Preliminary preparation was performed in the same manner as in Example 7A. Isolation of PBMCs from whole blood was performed in the same manner as in Example 1A, except that 40 mL of peripheral blood (whole blood) from a volunteer donor and 40 mL of PBS were used as starting materials. SeV infection was performed in the same manner as in Example 7A. When seeding cells on day 0 after establishment, the culture was performed in the same manner as in Example 1A, except that 2 mL of iMatrix-511 was added instead of 1 mL, and no scaffold material was added on day 1 after establishment. Cells were harvested without detaching them from the chamber.
[0162] (2) Results Microscopic observation 28 days after establishment revealed the formation of spheroids within the chamber. Photographs of spheroids at 24 days (Figure 14) and 28 days (Figure 14) after establishment are shown. Counting with a counter revealed approximately 424 spheroids and 4.21 × 10⁶ live cells at 28 days after establishment. 6 These cells were counted as such. Additionally, when 2 mL of iMatrix332 was added on day 28 after establishment, some adhesion occurred. When 3 mL of iMatrix332 was added on day 31, no further adhesion occurred, and the adhesion rate was visually estimated at about 30%.
[0163] (3) Succession Subculturing was performed 28 days after establishment.
[0164] (4) Flow cytometry Figure 14 shows the results of confirming the expression of GFP, which was loaded into the vector, and SSEA4 and TRA-1-60, which are representative iPS cell markers, in passages 1 and 3. SSEA4 and TRA-1-60 were confirmed by immunostaining using antibodies. These results confirmed that iPS cells were successfully established.
[0165] Example 12A (1) PBMC isolation from whole blood, SeV infection, and culture Except for using 1 mL of iMatrix-332 as the scaffold material during culture, PBMC isolation, SeV infection, and culture were performed from whole blood in the same manner as in Example 9A. As a result, microscopic observation 28 days after establishment revealed the formation of spheroids within the chamber. Counting with a counter revealed approximately 555 spheroids (some with colonies) and 2.59 × 10⁶ live cells 28 days after establishment. 6 These were counted as cells.
[0166] Example 13A (1) PBMC isolation from whole blood, SeV infection, and culture PBMC isolation, SeV infection, culture, and harvesting were performed from whole blood in the same manner as in Example 12A, except that the starting material consisted of 20 mL of whole blood and 20 mL of PBS, and 2 mL of iMatrix-332 was added as the scaffold material instead of 1 mL.
[0167] (2) Results Microscopic observation 28 days after establishment revealed the formation of spheroids within the chamber. A count using a counter revealed approximately 518 spheroids (some with colonies) and 7.46 × 10⁴ live cells after 28 days. 6 These cells were counted. Photographs of the cells on day 12 and day 16 after establishment are shown in Figure 15.
[0168] (3) Succession Subculturing was performed 21 days after establishment. (4) Flow cytometry The expression levels of GFP, SSEA4, and TRA-1-60, which were loaded into the vector, were confirmed one week after each passage in passages 1 and 3 (Figure 15). These results confirmed that iPS cells were successfully established.
[0169] Examples 23A and 24A The investigation of coating methods for scaffolding materials was carried out by establishing iPS cells using the same method as in Example 13A, except for the conditions shown in Table 4 below.
[0170] [Table 4]
[0171] The results of the study showed that when the scaffolding material was mixed with the cells and applied during cell seeding, the iPS cells that were established were 3D (spheroid) rather than 2D. When the scaffolding material was applied before cell seeding, the iPS cells that were established were 2D (colony). Furthermore, from the perspective of the amount of scaffolding material used, it was suggested that applying it before cell seeding is preferable (Figure 17).
[0172] Examples 29A and 30A (Summary) The process of monocyte differentiation in the cell processing device (Prodigy) was examined. (1) The medium and cytokines are as shown in Tables 5 to 8.
[0173] [Table 5]
[0174] [Table 6]
[0175] [Table 7]
[0176] [Table 8]
[0177] (2) The process is as follows. <day0> (i) AK03N 30 ml <feed> (ii) 200 mL of Essential 8 was added (total 130 mL). (iii) AK03N was diluted. (iv) The volume was reduced to 10 mL (AK03N was present in 3 / 23 of the 10 mL volume). (v) This process was repeated about twice to dilute AK03N as much as possible. (vi) The volume was reduced to 10 mL. (vii) Assume that Essential 8 is now 10 mL. <feed> (viii) 10 mL of Essential 8 containing 2x BMP4, 2x VEGF, and 2x CHIR was added thereto. (ix) The cells were mixed with 10 mL of Essential 8 in the chamber, resulting in a state where the cells were immersed in Essential 8 medium containing 1x BMP4, 1x VEGF, and 1x CHIR. (x) The cells were differentiated into monocytes (iMonocytes) using a cell processing device (Prodigy) (similar to the differentiation induction protocol in Example 2).
[0178] Example 29A Synthemax was applied as a scaffold material to the cell processing chamber (Prodigy chamber). After infection with the Sendai virus vector, from day 28, differentiation into monocytes was initiated within the chamber using the mechanism of the cell processing device (Prodigy) without removing the chamber from the device. From the start of differentiation into monocytes to day 20, the number of cells (5.43 x 10) was 7 Cells (Viability: 86%) were collected. Based on the expression results of CD14 and CD45-positive cells, which are markers of monocyte differentiation, the percentage of cells differentiated into monocytes was 6.85% of all viable cells (Figure 18). When GFP was examined by FACS, the group of cells with residual reprogramming factors (GFP+: 62.5%) showed very little CD14+ (0.077%) and were found to be less likely to differentiate into monocytes (Figure 18). On the other hand, cells with no residual reprogramming factors (GFP-: 34.8%) showed CD14+ (18.4%) and differentiated into monocytes, which was considered reasonable (Figure 18). These results suggest that the timing of induction initiation is important.
[0179] Example 30A Cells from Example 29A were re-seed in the chamber used in Example 29A, and macrophage differentiation was performed. Based on the expression results of CD14 and CD45-positive cells, which are markers for monocyte differentiation, the macrophage differentiation rate was 71.9% of all viable cells (Figure 19). Induction of differentiation into macrophages in 5.32 x 10 cells 7 In the cells, the experiment was started in a chamber, and the cells were harvested on day 6. The cell count was 9.8 x 10⁶. 6 The cells had a viability of 62%. When examined for GFP by FACS, only 1.17% of the cells were GFP+, indicating residual reprogramming factors. 95.1% were GFP-, meaning no residual reprogramming factors remained, and 66.4% were CD14+, indicating differentiation into macrophages (Figure 19).
[0180] Example 3 (1) Materials and methods iPS cells were produced using the Prodigy cell processing device in the same manner as in Example 1A, except that 20 ml of whole blood, 2.0 L of CytoTune(R)-iPS (MOI ≈ 1.0) and 100 μL of iMatrix-511 were used as starting materials. The produced iPS cells were then induced into cardiomyocytes in the same manner as in Example 1. We then investigated whether target cells (cardiomyocytic cells) could be isolated from the iPS cell-derived cardiomyocytes by utilizing the differences in autofluorescence within the cardiomyocytes.
[0181] The isolation of iPS cell-derived cardiomyocytes was performed in the same manner as in Example 1, except that a BD FACSymphony S6 cell sorter was used. The combinations of short-wavelength lasers and filters that can be excited by the FACSymphony are as follows. Hoechst (UV): Excitation wavelength (Ex) 375 nm / Maximum fluorescence (Em) 450 nm BV421 (Violet): Excitation wavelength (Ex) 405 nm / Maximum fluorescence (Em) 431 nm BV510 (Violet): Excitation wavelength (Ex) 405 nm / Maximum fluorescence (Em) 525 nm BB515 (Blue): Excitation wavelength (Ex) 488 nm / Maximum fluorescence (Em) 530 nm We tried all four combinations mentioned above and investigated the optimal combination of excitation wavelength and filter.
[0182] (2) Results Induced cardiomyocytes were unfolded according to the intensity of autofluorescence (Figure 20). Similarly, iPS cells were unfolded according to the intensity of autofluorescence (Figure 21). In addition, induced cardiomyocytes were stained with SIRPa (CD172a), CD31, CD49a, CD90b, and CD140b to identify cardiomyocyte-specific expression regions (Figure 22). Then, cardiomyocyte-specific expression regions for SIRPa(+) / CD31(-), CD49a(-), CD90b(-), and CD140b(-) were confirmed (Figure 22).
[0183] Next, a figure was created by overlaying the results from Figures 20 to 22 onto the same plot (Figure 23). Based on the created Figure 23, the gate settings to be used in the cell sorter were considered (Figure 24 (left)). Among the induced cardiomyocyte plots (gray), the combinations that seemed likely to separate the iPS cell plot (light gray) and the SIRPa plot (dark gray) with a high cardiomyocyte ratio were those developed using Ex375 / Em450 and Ex488 / Em530. Based on these results, a sorting gate was set in the SIRPa plot (dark gray) portion that did not include the iPS cell plot (light gray) and had a high cardiomyocyte ratio (Figure 24 (left)). Actual sorting was performed using the gate set as shown in Figure 24 (left) (Figure 24 (right)).
[0184] Furthermore, to evaluate the effectiveness of the gates set up as shown in Figure 24, the sample before sorting (left), the sample sorted by Gate-Others (center), and the sample sorted by Gate-CM (right) were stained with cardiac troponin T (cTNT), a cardiac muscle-specific marker, to confirm the myocardial percentage (Figure 25). As a result, it was confirmed that the sample sorted by Gate-CM had a higher myocardial percentage compared to the sample before sorting. Therefore, it was understood that by isolating the target differentiated cells based on the gates set up in this way, the differentiated cells can be produced simply and effectively. [Industrial applicability]
[0185] This invention is useful because it allows for the simple separation and purification of target differentiated cells and organoids without relying on labeling with antibodies or the like. Furthermore, this invention allows for the separation and purification of differentiated cells intended for production without any processing, and therefore is effective in producing differentiated cells suitable for clinical application. [Explanation of Symbols]
[0186] 100 sealed chambers 210-250 sealed containers for material supply A10 Connecting conduit V10 Pinch Valve F10 Peristaltic Pump< / feed> < / feed>
Claims
1. A method for producing differentiated cells derived from stem cells, comprising the step of isolating the differentiated cells from a cell population including stem cells and differentiated cells derived from the stem cells, based on the difference in autofluorescence between at least the stem cells and the differentiated cells.
2. The method according to claim 1, wherein the difference is determined by comparing the autofluorescence intensity of the stem cells, the autofluorescence intensity of the differentiated cells, and the expression level of an antigen specific to the differentiated cells.
3. The method according to claim 2, wherein the difference is determined by plotting at least two fluorescence intensities of the autofluorescence of the stem cells, at least two fluorescence intensities of the autofluorescence of the differentiated cells, and the expression level of an antigen specific to the differentiated cells on the same plane.
4. The method according to claim 3, wherein the two types of fluorescence intensities are fluorescence intensities having wavelengths of 500 nm to 550 nm and 430 nm to 500 nm.
5. The method according to claim 1, wherein the stem cells are embryonic stem cells, induced pluripotent stem cells, or mesenchymal stem cells.
6. The method according to claim 1, wherein the differentiated cells are nerve cells, blood cells, or cardiomyocytes.
7. The method according to claim 6, wherein the differentiated cells are cardiomyocytes.
8. The aforementioned stem cells are induced pluripotent stem cells, and the stem cells are cells produced using a cell processing device, The cell processing apparatus has a closed system section in which a sealed container for supplying material and a sealed chamber that can rotate for centrifugal separation are connected via a connecting conduit. The stem cells, while maintaining the closed nature of the closed system portion, are placed in the rotatable sealed chamber. The process of centrifuging blood cells from whole blood (s1), The process of bringing the reprogramming factor into contact with the blood cells (s2), The process of establishing induced pluripotent stem cells from the aforementioned blood cells (s3) The method according to any one of claims 1 to 7, produced by the method for producing induced pluripotent stem cells, performed in this order.
9. A method for enriching differentiated cells, comprising the step of removing undifferentiated cells from a cell population including stem cells and differentiated cells derived from the stem cells, based on the difference in autofluorescence between at least the stem cells and the differentiated cells.
10. The method according to claim 9, wherein the difference is determined by comparing the autofluorescence intensity of the stem cells, the autofluorescence intensity of the differentiated cells, and the expression level of an antigen specific to the differentiated cells.
11. The method according to claim 10, wherein the difference is determined by plotting at least two intensities of the autofluorescence of the stem cells, at least two intensities of the autofluorescence of the differentiated cells, and the expression level of an antigen specific to the differentiated cells on the same plane.
12. The method according to claim 11, wherein the two types of fluorescence intensities are fluorescence intensities having wavelengths of 500 nm to 550 nm and 430 nm to 500 nm.
13. The method according to claim 9, wherein the differentiated cells are nerve cells, blood cells, or cardiomyocytes.
14. The method according to claim 13, wherein the differentiated cells are cardiomyocytes.
15. The aforementioned stem cells are induced pluripotent stem cells, and the stem cells are cells produced using a cell processing device. The cell processing apparatus has a closed system section in which a sealed container for supplying material and a sealed chamber that can rotate for centrifugal separation are connected via a connecting conduit. The stem cells, while maintaining the closed nature of the closed system portion, are placed in the rotatable sealed chamber. The process of centrifuging blood cells from whole blood (s1), The process of bringing the reprogramming factor into contact with the blood cells (s2), The process of establishing induced pluripotent stem cells from the aforementioned blood cells (s3) The method according to any one of claims 9 to 14, manufactured by a manufacturing method carried out in this order.
